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ABSTRACT 
 
In the post-genome era, one of the most important topics of research is to edit or program 
genomic sequences and to generate desired phenotypes. Although virus-based strategies 
have long been developed to for efficient gene insertion, the random or semi-random 
integration can disrupt certain endogenous genes and cause unpredictable phenotypes. In 
contrast, targeted genome editing enables researchers to tailor genomic loci in a specific 
manner. Applications include studying gene functions, engineering microbes for 
industrial fermentation, improving traits in crop plants and livestock, treating human 
diseases, etc. This thesis describes my efforts on engineering transcription activator-like 
effector (TALE) nucleases (TALENs) as an efficient tool for targeted genome editing.  
Targeted genome engineering relies on the introduction of a site-specific double-
strand break (DSB) in a pre-determined genomic locus by a rare-cutting DNA 
endonuclease. Subsequent repair of this DSB by non-homologous end joining or 
homologous recombination generates the desired genetic modifications such as gene 
disruption, gene insertion, gene correction, etc. For this purpose, I have constructed 
TALEN architecture by fusing the DNA binding domain of TALE and a FokI non-
specific DNA cleavage domain. TALEs are isolated from the plant pathogenic bacteria 
from the genus Xanthomonas and their DNA binding domains are composed of a series 
of tandem repeats. Each repeat comprises 33–35 amino acids and recognizes a single 
nucleotide. The DNA recognition specificity is conferred by the highly variable amino 
acids at positions 12 and 13 (e.g., NI recognizes adenine, HD recognizes cytosine, NG 
recognizes thymine, and NN recognizes guanine and adenine). This simple code and 
iii 
independent DNA binding of the repeat units enable TALEs to bind to any custom-
designed DNA sequence. The fusion of a FokI cleavage domain makes TALENs a new 
class of artificial DNA endonucleases which serve as a powerful tool for targeted genome 
editing.  
To monitor in vivo activities of TALEN, I have constructed various reporter systems 
constructed in yeast and human cells. To maximize the genome editing efficiency of 
TALENs, I have optimized the TALEN scaffold by the truncation of N- and C-termini of 
TALEs. Two TALEN scaffolds were identified with efficient activity in modifying both 
yeast and human genomes. To further improve TALEN platform, I have constructed a 
high-throughput screening system and identified the SunnyTALEN architecture through 
directed evolution. Compared with the existing TALEN platform, SunnyTALEN shows 
significantly increased genome editing efficacy in both yeast and human cells. To 
demonstrate the application of TALEN technology in human therapeutics, I have 
corrected the sickle cell disease mutation in patient-derived induced pluripotent stem 
cells. The corrected stem cells can serve as a regenerative medicine for the treatment of 
human genetic disorders. Lastly, I have created a novel single-chain TALEN architecture, 
which can be used to decrease the payload for efficient TALEN delivery. 
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CHAPTER 1. INTRODUCTION 
 
1.1. Targeted genome editing 
Targeted genome engineering or editing enables researchers to modify genomic loci of 
interest in a precise manner, which has various applications in industry, agriculture and 
human therapeutics. Virus-based strategies have been developed to efficiently integrate 
an exogenous gene into a mammalian genome (1). However, the integration process is 
often random, which may disrupt certain endogenous genes and cause unpredictable 
phenotypes. For example, in the case of human gene therapy, insertional mutagenesis 
caused by random integration of viral vectors is a major safety concern, which limits the 
wide adoption of this technology (2,3). Chimeric zinc finger recombinases (4) and zinc 
finger transposases (5) have been developed to integrate foreign DNA into the genome in 
a more specific manner, but they are still in the preliminary stage and have met limited 
success. A more established strategy for targeted genome engineering relies on the 
introduction of a site-specific double-strand break (DSB) in a pre-determined locus by an 
engineered DNA endonuclease. Subsequent repair of this DSB by non-homologous end 
joining (NHEJ) or homologous recombination (HR) will generate desired genetic 
modifications (6). The NHEJ mechanism can disrupt a gene by introducing frame-shift 
mutations while the HR mechanism will result in gene deletion, gene insertion or gene 
correction (Figure 1.1). 
For an engineered DNA endonuclease to be widely used in targeted genome 
engineering, two criteria must be met: i) it must recognize a long DNA sequence with 
high specificity in order to avoid cytotoxic off-target DNA cleavage; ii) it must be readily  
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Figure 1.1. The DNA DSB generated by a site-specific endonuclease will be repaired by either NHEJ 
or HR, resulting in gene disruption, gene deletion, gene addition or gene correction.  
 
designed to recognize and cleave a defined sequence in the genome. Three major classes 
of DNA endonucleases have been developed as genome engineering tools, including 
engineered homing endonucleases (also called meganucleases), zinc finger nucleases, and 
transcription activator-like effector nucleases (TALENs).  
 
1.2. Engineered homing endonucleases 
Homing endonucleases (HEs), also known as meganucleases, represent a family of 
naturally occurring rare-cutting endonucleases, which can be found in all kingdoms of 
life. HEs specifically recognize and cleave long DNA sequences (14-40 bp), which 
represent a promising tool to promote chromosomal DSBs for targeted genome 
engineering (reviewed by (7,8)). Among all the identified HE families, members of the 
eukaryal and archael LAGLIDADG family exhibit the highest overall DNA recognition 
specificity. LAGLIDADG homing endonucleases (LHEs) use antiparallel β-sheets as a 
3 
DNA recognition module by forming a saddle on the DNA helix major groove, and the 
DNA cleavage is catalyzed by the divalent metal cations in the active site (Figure 1.2A) 
(9). Some HE proteins such as I-CreI and I-MsoI form homodimers and cleave 
palindromic or pseudo-palindromic target sites, while other members such as I-SceI and 
I-AniI are monomeric, cleaving non-palindromic DNA sequences. 
Several hundreds of HEs have been identified. However, the repertoire of DNA 
recognition sequences is very limited compared to the size of the human genome 
(>20,000 genes), making it nearly impossible to find a natural HE recognition site in a 
pre-determined genomic region. Therefore, HEs must be engineered to recognize and 
cleave target DNA sequences, which is a very challenging task due to the complex, 
highly cooperative network of protein-DNA contacts and the tight coupling of cognate 
site binding to subsequent catalysis of DNA bond cleavage (Table 1.1). Directed 
evolution strategies have been developed to modify the sequence specificity of known 
HEs (10,11). For example, Doyon and coworkers (12) and Chen and coworkers (13) 
successfully isolated I-SceI variants capable of cleaving novel DNA sequences by the 
help of a bacterial based in vivo selection system. Instead of creating or screening large 
protein libraries, the Baker group used computational protein design to reprogram HEs 
and successfully altered the specificity of I-MsoI and I-AniI (14-16). To engineer 
homodimeric HEs such as I-CreI to recognize novel non-palindromic targets, each 
monomer has to be engineered separately to target its palindromic site as the first step. 
Next, the two different I-CreI monomers can be co-expressed and heterodimerized upon 
binding the chimeric DNA sequence, resulting in cleavage (17). Using this strategy, 
however, cleavage-competent I-CreI homodimers may also form and cleave their  
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Figure 1.2. Schematic and structures of engineered site-specific endonucleases. Two perpendicular 
views are presented, with the DNA duplex shown in grey. (A) Homing endonuclease I-CreI (blue) 
binds to the target site as a dimer. Antiparallel β-sheets are used for DNA recognition and DNA 
cleavage is catalyzed by the magnesium ions (purple spheres) within the central catalytic core 
(adapted from (18), PDB no. 2VBL). (B) Zinc finger nucleases function as heterodimers and bind to 
DNA targets by zinc finger domains (orange). DNA cleavage is executed by the dimerization of FokI 
DNA cleavage domain (green). Zinc fingers coordinate zinc ions (cyan spheres) with a combination of 
cysteine and histidine residues. The α-helix of each zinc-finger interacts with three nucleotides in the 
DNA major groove (adapted from (19), PDB no. 1MEY). (C) TAL effector nucleases use central 
tandem repeats (pink) for DNA sequence recognition and the FokI DNA cleavage domain (green) for 
DNA cleavage. The TAL tandem repeats form a right-handed super-helical structure, binding to the 
major groove of DNA (adapted from (20), PDB no. 3V6T). 
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Table 1.1. Comparison of three tailored site-specific endonucleases.  
 Homing endonuclease Zinc finger nuclease TAL effector nuclease 
Typical length of 
recognition site 
14-40bp 
18-24 bp with 5-7bp 
spacer 
30-50 bp with 10-30 bp 
spacer 
Typical protein 
size 
<40 kD <30 kD* >100 kD
a
 
Modularity low medium high 
Advantages 
1. non-specific FokI DNA 
cleavage domain is not 
required 
2. High DNA cleavage 
efficiency 
1. relatively easy to tailor 
the substrate specifcity 
2. well characterized in 
terms of specificity, 
affinity and toxicity 
1. easy to tailor the 
substrate specifcity 
2. the length of the 
recognition site can be 
freely adjusted 
Disadvantages 
1. difficult to tailor the 
substrate specificity 
2. specificity and toxicity 
have not been determined 
systematically 
1. sequence bias; prefer G 
rich sequence 
2. some ZFNs exhibit off-
target cleavage and 
cytotoxicity 
1. no code for recognizing 
guanine specifically 
2. specificity and toxicity 
have not been determined 
systematically 
3. large protein size may 
cause difficulty in delivery  
a
 the protein size of each monomer 
 
respective palindromic sequences, which can limit the safety or efﬁcacy via off-target 
cleavages. With the help of computational protein design, Fajardo-Sanchez and 
coworkers (21) re-designed the interaction surface of I-CreI to obtain an obligate 
heterodimer, which prefers a single chimeric DNA sequence and prevents the formation 
of I-CreI homodimers. For a similar reason, single-chain I-CreI was created by inserting a 
polypeptide linker between two copies of the I-CreI genes (22-24). Based on the single-
chain architecture, Ulge and coworkers (25) used computational design to generate 
thousands of monomeric I-CreI variants with altered specificities at 16 different base pair 
positions in the 22 bp target site. The single-chain design not only decreased the rate of 
off-target cleavage and cytotoxicity, but also simplified the engineering process. 
Among all HEs, I-CreI is the first one whose DNA recognition specificity was 
successfully modified to target a defined sequence within the human genome. Alteration 
of local substrate specificity of DNA-binding subdomains may not perturb the overall 
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protein structure and function, making I-CreI certain degree of modularity. By combining 
rational design and high throughput screening, I-CreI variants were engineered to target 
the human RAG1 gene associated with severe combined immunodeﬁciency (26,27) and 
the human XPC gene associated with xeroderma pigmentosum (18,28). Similarly, several 
I-CreI variants were generated to cleave Herpes simplex virus type 1 (HSV1) genome 
sequences (29). Moreover, single-chain I-CreI was used to induce high levels of gene 
targeting at the endogenous human RAG1 gene locus (27,30). In addition, Takeuchi and 
coworkers (31) used I-OnuI as a template and created a variant to cleave a sequence 
within the monoamine oxidase B (MAO-B) gene in human cells. Since this gene is a 
potential therapeutic target for a variety of neurodegenerative disorders, targeted 
disruption or modifications of the MAO-B gene might have great value for future clinical 
research. 
 
1.3. Zinc finger nucleases 
Zinc finger nucleases (ZFNs) are artificial DNA nucleases constructed by fusing several 
zinc finger domains to the sequence-independent cleavage domain of the type IIS 
restriction endonuclease FokI (32). Zinc finger domains serve as DNA recognition 
modules, and modifying the zinc finger domains can target the ZFNs to novel DNA 
sequences. A typical zinc finger domain contains an α-helix recognizing a specific DNA 
triplet. Therefore, a typical ZFN monomer containing 3 or 4 zinc finger domains 
recognizes a 9 or 12 bp DNA target site. Since the non-specific DNA cleavage domain of 
FokI functions as a dimer and has the highest cleavage efficiency in the inverse 
orientation (33), the typical custom-designed ZFN functions as a heterodimer recognizing 
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an 18-24 bp DNA sequence with a 4-6 bp spacer between each half site (Figure 1.2B). 
Compared with the engineered homing endonucleases, custom-designed ZFNs are easier 
to construct due to their moderate degree of modularity (Table 1.1). Multiple platforms 
such as the CompoZr
TM
 service, modular assembly, Oligomerized Pool Engineering 
(OPEN), and Context Dependent Assembly (CoDA) have been used to generate site-
specific ZFNs (reviewed by (34-36)). Because several zinc finger domains can tolerate 
mismatched DNA bases, off-target ZFN cleavage has been reported (37,38). The 
recognition of secondary degenerate sites of ZFNs will generate undesired genomic 
DSBs and result in unexpected side effects. Therefore, the sequence fidelity of ZFNs has 
to be improved for future ZFN design because it is critical to their safe and successful 
application in targeted genome engineering (Table 1.1). Recent advances in the ZFN 
technology involve a large number of applications such as gene disruption, gene insertion, 
gene correction, and chromosomal rearrangement (Figure 1.1), as will be highlighted 
below.  
 
1.3.1 Gene disruption 
The errors introduced during NHEJ-mediated chromosomal DSB repair can be used to 
achieve gene disruption (Figure 1.1). This approach has been applied in various 
mammalian cells to efficiently knock out targeted genes in a single step (recently 
reviewed by (36)). There are ongoing clinical trials for the treatment of human 
immunodeficiency virus (HIV) infection, which is based on ZFN-mediated CCR5 gene 
disruption (39,40). Recently, Cradick and coworkers (41) described a novel therapeutic 
strategy for treatment of hepatitis B by using ZFNs to target the hepatitis B virus genome. 
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Besides human cells, ZFNs were successfully applied to other mammals such as rat 
(42,43), rabbit (44) and pig (45). Moreover, in addition to NHEJ-mediated gene 
disruptions, Zou and coworkers inactivated the endogenous PIG-A locus associated with 
paroxysmal nocturnal hemoglobinuria in human embryonic stem cells (ESCs) and 
induced pluripotent stem cells (iPSCs) by DSB-induced HR (46). Successful HR-
mediated targeting resulted in the insertion of an antibiotic selection cassette into the 
PIG-A gene exon, thereby inactivating the PIG-A gene. 
 
1.3.2 Gene insertion 
Precise gene insertion can be achieved by ZFN-induced DNA repair (Figure 1.1). 
Hockemeyer and coworkers (47) reported the highly efficient targeting of three genes in 
human iPSCs via ZFN-based HR-mediated genome insertion. Specifically, they 
successfully integrated the enhanced green fluorescent protein (eGFP) reporter gene into 
the OCT4, AAVS1 and PITX3 loci. Note that the AAVS1 locus within the PPP1R12C gene 
on chromosome 19 is considered as a ‘safe harbor’ for addition of a transgene into the 
human genome (48). DeKelver and coworkers (49) described the use of ZFNs to insert 
various expression cassettes into the AAVS1 locus for isogenic transgenesis application. 
ZFN-mediated gene insertion turned out to be efficient (at a frequency of up to 15%) in 
both transformed cell lines (K562, HeLa, HEK293, U2OS, and others) and primary 
human cells (fibroblasts and ESCs). It was demonstrated that ZFN-driven gene addition 
into the AAVS1 locus did not introduce any adverse effect on the cell resulting from its 
disruption. Moreover, both promoterless (driven by the native PPP1R12C gene promoter) 
and promoter-containing inserts placed into the AAVS1 locus exhibited consistent gene 
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expression levels over 50 cell generations. Later, Zou and coworkers (50) integrated a 
single-copy gp91(phox) gene into the AAVS1 locus for treatment of the X-linked chronic 
granulomatous disease (X-CGD). X-CGD patients have a defect in neutrophil 
microbicidal reactive oxygen species (ROS) generation because of the gp91(phox) 
deficiency. With the help of a ZFN-induced DSB, a therapeutic gp91(phox) minigene was 
inserted into one allele of the AAVS1 locus in the X-CGD iPSCs without off-target 
insertions, which complemented the gp91(phox) gene deficiency and substantially 
restored neutrophil ROS production. 
 
1.3.3 Gene correction 
Gene correction is mediated by DSB-induced HR, which can be exploited for gene 
replacement, especially for the treatment of monogenic diseases. Compared with gene 
insertion, in situ gene correction is more challenging because the designed ZFN cleavage 
site must be close to or directly at the site of the mutation (Figure 1.1). Through site-
specific chromosomal DSBs induced by ZFNs, Sebastiano and coworkers (51) 
demonstrated HR-mediated efficient correction of the sickle cell anemia mutation in 
patient-derived human iPSCs. Two pairs of ZFNs were constructed by the publicly 
available OPEN method (52) to target the disease-causing β-globin gene. They first used 
those ZFNs to simultaneously correct the E6V mutation and insert a drug-resistance 
cassette into a neighboring intron 58 or 82 bp downstream of the ZFN cleavage sites. 
Isolation of drug-resistant clones and PCR screening followed by DNA sequencing 
enabled them to identify several iPSC clones containing the successfully corrected allele. 
Next they used the Cre recombinase to excise the selection gene cassette flanked by the 
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loxP sites, leaving a residual 34 bp loxP site “scar” in the intron of the corrected β-globin 
gene. Around the same time, Zou and coworkers (53) achieved site-specific gene 
correction of the β-globin gene in patient-derived human iPSCs. The ZFNs they used 
were custom designed by CompoZr
TM
 from Sigma-Aldrich (St. Louis, MO, USA). A 
similar two-step strategy was used to correct the sickle cell disease causing mutation: (i) 
Correction of the E6V mutation by ZFN-induced HR and integration of a loxP-flanked 
drug-resistant cassette into a neighboring intron; (ii) Cre recombinase-mediated excision 
of the drug-resistant cassette. To evaluate the gene expression of the corrected β-globin 
gene, they differentiated the corrected iPSCs into erythroid cells and surprisingly 
discovered that the expression level of the corrected β-globin gene was partially repressed. 
Since Cre-recombinase mediated gene excision in step (ii) left a residual loxP sequence 
in the intron, it is possible that the remaining loxP “scar” interfered with the 
transcriptional regulatory elements and thus altered the gene expression from the targeted 
allele. In addition to the unpredicted effect from the residual loxP site, such a strategy 
may not be applicable to all genes, especially when the location of the desired editing 
events is away from the intron region. 
Instead of using the Cre/loxP recombination system that leaves small ectopic 
sequences in the targeted genome, Yusa and coworkers combined ZFN with the piggyBac 
technology and achieved a “scarless” gene correction in patient-derived iPSCs (54). 
piggyBac is a moth-derived DNA transposon, which enables the removal of transgenes 
flanked by its inverted repeats without leaving any residual sequences (55). To correct the 
single mutation (E342K) in the A1AT gene causing α1-antitrypsin deficiency, ZFN pairs 
were designed to specifically cleave the mutation site. Through ZFN-induced HR, they 
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corrected the A1AT gene mutation and simultaneously inserted a PGK-puroΔtk cassette 
flanked by piggyBac repeats into the TTAA site. Targeted clones were isolated by 
puromycin selection. Next, the selection cassette was excised from the iPSC genome by 
transient expression of the piggyBac transposase and subsequent counter-selection, 
leaving no residual ectopic sequences in the targeted allele. Not only did their approach 
achieve seamless gene correction of diseased human iPSCs, but also enabled biallelic 
correction with high efficiency. Without using a selectable marker, Soldner and 
coworkers employed a selection-free targeting strategy (56). Briefly, given the high gene 
editing activity of the ZFNs, they constructed a donor vector lacking a selection cassette, 
consisting of only a homology arm flanking the ZFN cleavage site carrying a wild-type 
α-synuclein gene. An eGFP-expressing plasmid was coelectroporated into Parkinson’s 
disease patient-derived iPSCs together with the donor construct and ZFN-expression 
vectors to enrich transfected cells by fluorescence-activated cell sorting. One correctly 
targeted clone with the A53T (G209) mutation repaired was isolated after screening 240 
single-cell-derived clones by Southern blot analysis. The high efficiency suggests that 
one could isolate corrected clones by dilution cloning without going through drug 
selection. 
 
1.3.4 Chromosomal rearrangements 
Chromosomal rearrangements include large-scale gene deletions, insertions, 
duplications and inversions, which are associated with many genetic diseases and cancer 
(57). ZFNs have been utilized to generate targeted chromosomal rearrangements, which 
enables researchers to study gene functions at the genomic level (Figure 1.3). Brunet and  
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Figure 1.3. The concurrent DSBs generated by two endonucleases on different chromosomal loci will 
be ligated by the NHEJ mechanism, resulting in chromosomal deletion, inversion or duplication. 
 
coworkers (58) simultaneously introduced two pairs of ZFNs recognizing the PPP1R12 
gene on chromosome 19 and the IL2Rγ gene on the X chromosome into human cells, 
respectively. The concurrent DSBs at the two endogenous loci on different chromosomes 
induced chromosomal translocations between chromosome 19 and the X chromosome via 
NHEJ-mediated DSB repair. Using a similar approach, Lee and coworkers (59) used 
engineered ZFNs to generate targeted deletions of genomic segments in human cells. 
They designed two ZFN pairs to generate two concurrent DSBs in the same chromosome 
(Figure 1.3). The breakpoint joined together by endogenous NHEJ resulted in targeted 
deletions of the genomic segment between the two ZFN cleavage sites. By applying this 
method to the HEK293T cell line, they successfully deleted predetermined genomic DNA 
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segments in the range of ~729 bp to 15 Mb with frequencies of 0.1% to 10%. In addition 
to genomic deletions, they demonstrated that two concurrent DSBs introduced by ZFN 
pairs were sufficient to promote frequent genomic inversions and duplications in human 
cells with frequencies ranging from 0.01% to 5% (60). Harnessing various combinations 
of two ZFNs, they achieved duplications of genomic DNA between the two cleavage 
sites whose length ranged from 230 kb to 835 kb (Figure 1.3). They also demonstrated 
that the two concurrent genomic DSBs from ZFN cleavages induced inversions of 15 kb 
to 15 Mb DNA segments in the human genome (Figure 1.3). As proof of concept for 
therapeutic application of this technique, they constructed a ZFN pair to target the intron 
1 homolog in the human F8 gene, whose inversion causes severe hemophilia A (61). The 
genomic DSB generated by the ZFN pair induced the inversion of the 140 kb DNA 
segment bearing the promoter and exon 1 of the F8 gene with a frequency of 0.2%-0.4%. 
Their strategy demonstrated the promise of restoring genomic integrity in severe 
hemophilia A patients by reverting the inverted DNA segment back to the wild-type 
orientation. 
 
1.4. TALENs 
Even though ZFNs have been used for targeted genome editing in various organisms, two 
major limitations prevent their wider applications. ZF domains have limited modularity 
due to the context-dependent DNA-binding effects, making it difficult for ZFNs to target 
any desired DNA sequence (62). Moreover, lack of specificity of some ZF domains can 
generate off-target cleavage, leading to undesired mutations and chromosomal 
aberrations (38,63). Recently, TALENs have rapidly emerged as an alternative genome  
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Figure 1.4. Schematic of TALEN architecture. A TALEN is composed of a NTS (pink box), a central 
repeat domain, a CTS (cyan box) and a FokI catalytic domain (orange oval). The central repeat 
domain comprises a series of repeat units that are responsible for specific recognition of thymine (red 
boxes), adenine (green boxes), cytosine (blue boxes) and guanine (yellow boxes). The formation of a 
heterodimer by two TALENs in a tail-to-tail orientation at the target site executes a site-specific DNA 
DSB. The TALE binding sites on the target DNA are shown in black and the spacer is shown in grey.  
 
editing tool to ZFNs (recently reviewed by (64)). Similar to ZFNs, TALENs use the non-
specific FokI domain as the DNA cleavage module and function as dimmers (Figure 
1.2C and Figure 1.4). However, the DNA binding domains of TALENs are composed of 
a series of tandem repeats as in TALEs of the plant pathogenic bacteria from the genus 
Xanthomonas (as reviewed in (65,66)). Each repeat comprises 33-35 aa and recognizes a 
single nucleotide. The last repeat typically has only 20 aa, and is therefore called a ‘half-
repeat’. The DNA recognition specificity is conferred by the highly variable amino acids 
at positions 12 and 13 (e.g. NI recognizes adenine, HD recognizes cytosine, NG 
recognizes thymine, and NN recognizes guanine and adenine) (67,68). Unlike the 
context-dependent DNA binding of ZFNs, TALENs can be easily and rapidly constructed 
to target essentially any DNA sequence due to the simple protein-DNA code and the 
modular nature. In addition, TALENs exhibit significantly reduced off-target effects and 
cytotoxicities compared with ZFNs, making them an efficient genome editing tool 
15 
(69,70). Within the last three years, TALENs have been widely applied to modify 
endogenous genes in a variety of organisms (Table 1.2). Applications include studying 
gene functions in model organisms, improving traits in crop plants and livestock, 
generating disease models, and treating genetic disorders in humans. In this article, we 
provide a comprehensive review of TALEN technology including the optimization of the 
scaffold, improvement of the DNA recognition specificity, and assembly of TALE repeat 
arrays. Due to the ease of design and high efficiency of genome editing, TALENs have 
opened up many new avenues for basic and applied biological research.  
 
1.4.1. Scaffold optimization 
The original TALEN construction was reported by two independent groups. Li and 
coworkers fused the full-length natural TALE (AvrXa7 and PthXo1) with the FokI 
catalytic domain, creating the TALENs bearing a 288 aa N-terminal segment (NTS) and a 
295 aa C-terminal segment (CTS) (71). Based on a yeast reporter assay, the optimal 
spacer length between the two TALEN binding sites was determined to be 16-31 bp 
(Table 1.3). Alternatively, the TALENs created by Christian and coworkers encompasses 
a 287 aa NTS and a 231 aa CTS (72). This scaffold allows efficient DNA cleavage 
against target sites with 13-30 bp spacers (Table 1.3). Since naturally-occurring TALEs 
are transcription activators from a plant bacterial pathogen, their NTSs harbor protein 
secretion signal peptides while their CTSs contain nuclear localization signal peptides 
and a transcription activator domain (73). These sequences can impair the catalytic 
activity when fused with the FokI cleavage domain. To identify the optimum TALEN 
architecture with highest cleavage efficiency and minimal peptide portion, scaffold  
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Table 1.2. Applications of TALENs for targeted genome editing in various organisms.  
Organisms Genes Ref. 
Arabidopsis thaliana ADH1 (74) 
Brachypodium BdABA1, BdCKX2, BdCOI1, BdHTA1, BdRHT, BdSBP, BdSMC6, BdSPL (75) 
Cattle 
(Bos taurus) 
ACAN, GDF8, GGTA, PRNP (76) 
Cricket 
(Gryllus imaculatus) 
Gb′lac2 (77) 
Frog 
(Xenopus tropicalis) 
ets1, foxd3, grp78/bip, hhex, noggin, ptf1a/p48, sox9, tyr, vpp1 (78,79) 
Fruitfly 
(Drosophila 
melanogaster) 
CG9797, yellow (80) 
Hamster 
(Cricetulus griseus) 
FUT8 (81) 
Human 
(Homo sapiens) 
ABL1, AKT2, ALK, ANGPTL3, APC, APOB, ATGL, ATM, AXIN2, BAX, 
BCL6, BMPR1A, BRCA1, BRCA2, C6orf106, CIITA, CBX3, CBX8, 
CCND1, CCR5, CDC73, CDK4, CELSR2, CFTR, CHD4, CHD7, 
CTNNB1, CYLD, DDB2, DDX60, DHX58, DHX9, DICER1, EIF2AK2, 
EIF2C2, ERCC2, EWSR1, EXT1, EXT2, EZH2, FANCA, FANCC, FANCF, 
FANCG, FES, FGFR1, FH, FLCN, FLT4, FOXO1, FOXO3, GLI1, 
GLUT4, HBB, HDAC1, HDAC2, HDAC6, HMGA2, HOXA13, HOXA9, 
HOXC13, HPRT1, IFI44L, IFIT1, IFIT2, IL2RG, JAK2, KRAS, 
LINC00116, MAOA, MAP2K4, MB21D1, MDM2, MET, MLH1, MSH2, 
MUTYH, MYC, MYCL1, MYCN, NAMPT, NBN, NCOR1, NCOR2, 
NDUFA9, NLRC5, NTF3, NUB1, OASL, OCT4, PDGFRA, PDGFRB, 
PHF11, PHF8, PITX3, PLA2G4A, PLIN1,PMS2, PPP1R12C, PTCH1, 
PTEN, QRICH1, RARA, RBBP5, RECQL4, RET, RIPK4, RTP4, RUNX1, 
SDHB, SDHC, SDHD, SETDB1, SIRT6, SMAD2, SORT1, SS18, STAT1, 
STAT6, SUZ12, TBK1, TFE3, TP53, TRIB1, TSC2, TTN, UNC93B1, VHL, 
XPA, XPC 
(69,70,7
4,82-90) 
Medaka 
(Oryzias latipes) 
DJ-1 (91) 
Mouse 
(Mus musculus) 
Pibf1, Sepw1 (92) 
Nematode 
(Caenorhabditis 
elegans) 
ben-1 (93) 
Rat 
(Rattus norvegicus) 
BMPR2, IgM (94,95) 
Rice 
(Oryza sativa L.) 
Os11N3, OsBADH2, OsCKX2, OsDEP1, OsSD1 (75,96) 
Silkworm 
(Bombyx mori) 
BmBlos2 (97,98) 
Swine 
(Sus scrofa) 
AMELY, DMD, GDF8, GGTA, GHRHR, IL2Rg, p65, RAG2, RELA, SRY (76) 
Tobacco 
(Nicotiana tabacum) 
SurA, SurB (99) 
Yeast 
(Saccharomyces 
cerevisiae) 
ADE2, LYS2, URA3 (100) 
Zebrafish 
(Danio rerio) 
aanat2, abcc9, adora1b, adora2aa, bmi1, cdh5, clc, crhr1, dip2a, elmo1, 
epas1b, fgf21, fh, golden, gpr103a, gria3a, hdc, hey2, hif1ab, ikzf1, jak3, 
moesina, myod, nmu, npy, phf6, pmch, pmchl, ponzr1, ppp1cab, prok2, 
prokr1, prokr2, ptpmt1, qrfp, ryr1a, ryr3, scl6a, tbx6, tgfa, tnikb, vip 
(101-
107) 
17 
Table 1.3. Engineered TALEN scaffolds with different NTSs and CTSs.  
NTS 
(aa) 
CTS 
(aa) 
Spacer  
(bp) 
Reporter system References 
288 295 16-31 β-galactosidase assay in yeast (71) 
288 285 16
a
 
transient expression assay in 
tobacco leaves 
(108) 
287 231 13-30 β-galactosidase assay in yeast (72) 
287 63 15
a
 mutagenesis in medaka embryos (91) 
207 63 14-32 β-galactosidase assay in yeast (89) 
207 31 10-16 β-galactosidase assay in yeast (89) 
153 47 12-21 dsEGFP assay in HEK293 (70) 
153 17 12 dsEGFP assay in HEK293 (70) 
136 63 12-20 Surveyor nuclease assay in K562 (84) 
136 28 12-13 Surveyor nuclease assay in K562 (84) 
136 18 13-16 β-galactosidase assay in yeast (109) 
a
 The spacer length was not optimized in the study 
 
optimization has been carried out by several groups. Using a truncated NTS with only 
136 aa, Miller and coworkers constructed a series of TALENs by trimming the CTS 
between the central repeat units and the FokI nuclease domain (84). This study found that 
different TALEN scaffolds prefer different spacer length between each TALEN binding 
site. One TALEN scaffold was identified bearing a 63 aa CTS, which could drive 
efficient gene modification in human cells when separated by 12-20 bp spacers (Table 
1.3). This scaffold has since been widely applied for efficient genome editing in various 
species (79,82,85,93,94,102,105-107). In addition, another TALEN scaffold bearing only 
a 28 aa CTS with a narrower separation range of 12-13 bp was identified (Table 1.3). 
Later, Mussolino et al. and Christian et al. reported TALENs with even shorter CTSs that 
exhibit narrow optimal ranges of spacers (Table 1.3) (70,109). A systematic study was 
carried out by Sun and coworkers who constructed 10 different TALEN scaffolds with 
various NTSs and CTSs (89). The DNA cleavage activity of each scaffold was assayed 
against 10 substrates with different spacers in a yeast reporter system. Based on this 
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10×10 matrix, two TALEN scaffolds with high DNA cleavage efficiency in both yeast 
and human cells were identified. One bearing a 207 aa NTS and a 31 aa CTS prefers 
target sites with 10-16 bp spacers while another bearing a 207 aa NTS and a 63 aa CTS 
has highest efficiency when separated by 14-32 bp spacers (Table 1.3). It is noteworthy 
that the TALEN with a 50 aa NTS has no catalytic activity against any target sites. Later 
on, Gao and coworkers solved the crystal structure of the TALE NTS and discovered an 
extended N-terminal DNA binding region composed of the 127 aa immediately preceding 
the central repeat units (110). The 127 aa NTS features four continuous repeats. Each 
repeat contains two α-helices and an intervening loop (Figure 1.5A), a structural feature 
highly similar to that of the central repeat unit. Although the 127 aa NTS does not confer 
sequence specificity, it is crucial for DNA binding. This feature explains why all the 
effective TALEN scaffolds have at least 127 aa preceding the central repeat units (Table 
1.3).  
A second-generation GoldyTALEN scaffold has been demonstrated to improve the 
genome editing efficiency in zebrafish (101). GoldyTALEN is based on a scaffold 
previously reported by Miller and coworkers (84) which consists of a 136 aa NTS and a 
63 aa CTS. However, it has 9 different aa substitutions at the NTS and 5 different aa 
substitutions at the CTS. Using the GoldyTALEN scaffold and zebrafish delivery system, 
certain loci were modified with 100% efficiency. Moreover, they provided the first 
example of HR-based genome editing in zebrafish using single-stranded DNA as a donor. 
The GoldyTALEN scaffold was also applied for efficient gene knockout in livestock (76). 
Because the FokI catalytic domain must dimerize to become active, two TALEN 
subunits are assembled as heterodimers at the cleavage site. However, cleavage- 
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Figure 1.5. Crystal structures of TALEs. (A) The TALE NTS features four continuous repeats, which 
are important for the DNA binding affinity (adapted from (110)). (B) Overall structure of the TALE 
PthXo1 central repeat domain in complex with its target site (adapted from (111)). (C) Interaction of 
RVD HD with cytosine (adapted from (110)). Hydrogen bonds are indicated by cyan lines. (D) 
Interaction of RVD HG with thymine (adapted from (111)). A nonpolar van der Waals interaction is 
shown in a dotted line. (E) Interaction of RVD NG with thymine (adapted from (110)). (F) Interaction 
of RVD NI with adenine (adapted from (111)). (G) Interaction of RVD NN with guanine (adapted 
from (111)). (H) Interaction of RVD NG with 5-methyl cytosine (adapted from (112)). (I) Interaction 
of RVD N* with 5-methyl cytosine based on a structural model. (J) Interaction of the NTS with the 
5’- preceding thymine. (Adapted from (111)). The coloring of the two repeats in TALE NTS matches 
that in Figure 1.5A. 
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competent homodimers composed of each subunit may also form and generate off-target 
cleavage, which can limit safety or efficiency. To address this limitation, obligate 
heterodimer mutations were introduced at the dimer interface of the FokI cleavage 
domain which prevented homodimerization based on electrostatic and hydrophobic 
interactions. The creation of FokI variants that preferentially heterodimerize successfully 
reduced off-target cleavage of ZFNs and relieved toxicity (113-115). A similar principle 
was applied to TALENs by Cade and coworkers (102) for the generation of zebrafish 
knockout lines. The heterodimeric TALENs show similar or even greater activities than 
their homodimeric counterparts. Moreover, the TALENs constructed with heterodimeric 
FokI domains induced smaller numbers of abnormal or dead embryos, indicating reduced 
toxicity. This obligate heterodimeric TALEN configuration has also been reported by 
other groups for gene knockout studies (79,104,105).  
 
1.4.2 DNA recognition specificity 
The DNA recognition specificity of TALENs is conferred by the repeat-variable 
diresidues (RVDs) at positions 12 and 13 of each repeat. More than 20 different RVDs 
have been identified in TALEs, among which NI, NG, HD, NN, and HG are the most 
common ones recognizing the nucleotides A, T, C, G/A, and T, respectively (67,68). 
Based on crystal structures, TALE binds to target DNA as a right-handed superhelix 
(Figure 1.5B). Each repeat unit forms a left-handed, two-helix bundle that presents an 
RVD-containing loop to the DNA major groove (20,111). The first residue of each RVD 
(residue 12 of each repeat), either His or Asn, does not contact DNA directly. Instead, the 
side chain forms a hydrogen bond to the backbone carbonyl oxygen of Ala at position 8 
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(Ala
8
) of each repeat, stabilizing the local conformation of the RVD-containing loop 
(Figure 1.5 C-E). Sequence-specific contacts of TALEs to target DNA are made by the 
second residue of each RVD (residue 13 of each repeat) to the corresponding base on the 
sense strand. In the HD RVDs specific for C nucleotides, the carboxylate oxygen of 
Asp
13
 forms a hydrogen bond to the amine group of cytosine, which excludes the other 
bases through physical or electrostatic clash (Figure 1.5C). In the case of NG and HG 
RVDs specific for T nucleotides, the backbone α carbon of the Gly13 makes a nonpolar 
van der Waals contact with the methyl group of the opposing thymine base, which is less 
favorable for the other bases (Figure 1.5 D & E). In the NI RVDs specific for A 
nucleotides, the aliphatic side chain of Ile
13
 makes nonpolar van der Waals interactions to 
C8 and N7 of adenine, which reduces the binding affinity to the other bases (Figure 
1.5F). NN RVDs are commonly used to recognize G nucleotides. The side chain of Asn
13
 
residue makes a hydrogen bond with the N7 nitrogen of the opposing guanine base 
(Figure 1.5G). But similar interaction might be made with the N7 nitrogen of adenine, 
which makes NN RVDs associate with A and G nucleotides with almost identical 
frequency. Because HD and NN RVDs form hydrogen bonds with DNA bases, the 
binding affinities of HD to cytosine and NN to guanine are much stronger than the van 
der Waals contacts of NI to adenine and NG/HG to thymine. It has been suggested to 
incorporate at least 3-4 strong RVDs for the construction of efficient TALENs (116).  
The lack of specific RVDs to recognize guanine limits TALENs’ broader applications 
because non-specific binding can generate off-target cleavage, resulting in unexpected 
genomic instability and cytotoxicity. Morbitzer and coworkers discovered that the NK 
RVDs can facilitate specific targeting of G nucleotides through in planta function 
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analysis (117). Based on the SELEX assay, Miller and coworkers provided in vitro 
evidence that RVD NK has a much stronger preference for guanine over adenine, which 
represents a promising code for the specific recognition of G nucleotides (84). However, 
substitution of RVD NN with NK significantly reduced TALEN activity in zebrafish 
embryo (105). Substantially lower activities in NK containing TALEs have also been 
observed in plants and in mammalian cells (116,118). Therefore, RVD NK is not ideal 
for guanine recognition because the improvement in specificity sacrifices efficiency. 
Alternatively, NH has been reported as a competent guanine-specific RVD, which has 
much higher efficiency than RVD NK (116,118). Computational modeling analysis 
showed that the imidazole ring on the His
13
 of the NH RVD has a compact base-stacking 
interaction with the guanine base, suggesting a possible mechanism for its increased 
specificity for G nucleotide while maintaining the binding affinity (118).  
Although successfully used in various cellular contexts, TALE DNA binding domains 
have been reported to be incapable of targeting methylated DNA (119). Often considered 
as the fifth base, 5-methyl cytosine (5mC) is a major epigenetic mark and widely 
distributed in fungi, plant and mammalian genomes (120). In addition, 5mC has been 
identified in CpG islands of many promoters, which are important regulatory regions for 
genome modification (121). Recently, two groups discovered that RVD NG and N* (an 
asterisk indicates a deletion at residue 13 in the repeat unit) can accommodate 5mC 
efficiently in vitro and in vivo (112,122). Thymine is structurally similar to 5mC, with the 
only difference at position 4, which is not involved in binding to TALE repeats. This 
observation indicates that the NG RVD specific for thymine might be used to recognize 
5mC. The protein crystal structure solved by Deng and coworkers shows that lack of side 
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chain of Gly
13
 in NG RVDs provides sufficient space to accommodate the 5-methyl 
group of 5mC and allows the formation of van der Waals contacts (Figure 1.5H) (112). 
Because RVDs are followed immediately by two conserved Gly residues, N* is roughly 
equivalent to NG except for a shortened RVD loop (Figure 1.5I). Using N* to code for 
5mC, Valton and coworkers demonstrated the first example of TALEN-mediated 
modification at a methylated locus in human cells (122). Accommodation of 5mC by 
TALE repeats through the RVD NG or N* extends the DNA recognition code and 
enables researchers to design TALENs to target hypermethylated DNA regions, which 
has great potential in epigenetics studies and human therapeutic applications.  
All naturally-occurring TALE target sites are preceded by a 5’-thymine at position 0, 
which was previously believed to be essential for TALE function (67,68). The TALE 
crystal structure reveals that two degenerate repeats prior to the central repeat domain 
appear to cooperate to specify the conserved 5’-thymine (111). The indole ring of a Trp 
residue in the repeat R(-1) forms a van der Waals contact with the methyl group of the 
thymine base, suggesting a possible mechanism for the conserved specificity at position 0 
(Figure 1.5J). Sun and coworkers reported that TALENs with shorter CTSs (31 aa) show 
higher efficiency against natural TALE recognition sites preceded by a 5’-T than that 
against unnatural TALE sites preceded by A, C or G. However, TALEN variants with 
longer CTSs (63-117 aa) are capable of cleaving unnatural DNA substrates with similar 
efficiency compared with that of natural TALE sites (89). Other studies also provided 
evidence that a thymine at position 0 is not strictly required for TALEN activity 
(84,123,124). Notably, there are nine leucine zipper-like heptad repeats closely linked to 
the C terminus of the TALE central repeat domain (125). These leucine-rich repeats may 
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mediate TALE/DNA interactions and increase DNA binding affinity, making the 5’-T 
less of a requirement. Detailed structural studies could help solve this uncertainty. The 
requirement of a preceding 5’-T can be mitigated using certain TALEN scaffolds, 
allowing greater flexibility in choosing target sites in genome editing endeavors.  
 
1.4.3. Assembly of TALE repeat arrays 
Because of the high similarity between each TALE repeat unit, it is challenging to 
construct plasmids encoding long arrays of TALE repeats. To address this limitation, 
numerous methods have been developed to assemble the highly repetitive TALE central 
repeat domains rapidly and cost-effectively (64). Based on a standard cloning strategy, 
Sander and coworkers described a restriction enzyme and ligation (REAL) method, in 
which single TALE repeats are joined together using routine restriction digestion and 
ligation techniques (107). Initially, they constructed a library of plasmids encoding 
various individual TALE repeats by DNA synthesis. In the assembly step, two TALE 
repeats are first joined together by ligating compatible overhangs generated by digestion 
with restriction endonucleases. Next, the ligation product encoding two TALE repeats is 
joined with another TALE repeat dimer in the same manner, resulting in a DNA fragment 
encoding four TALE repeats. This process continues in an iterative fashion until a TALE 
repeat array of the desired length is assembled (Figure 1.6A). Using a large plasmid 
library of pre-assembled multiple TALE repeats, REAL can be performed in a more rapid 
and less labor-intensive fashion, which is referred to as REAL-Fast (126). With the help 
of isocaudamer restriction enzymes (e.g. NheI and SpeI), a unit assembly method has 
25 
been described for building long TALE repeat arrays in the similar hierarchical fashion 
(105). 
Utilization of Golden Gate cloning has greatly facilitated and accelerated the 
synthesis of TALE genes (74,86,100,127-130). Golden Gate cloning has been developed 
to overcome the difficulty of assembling the monomers into ordered multimer arrays 
(131). It employs type IIS restriction endonucleases that cut outside of their recognition 
sequences and produce nonpalindromic, 4 bp 5’-overhangs. Since the recognition and 
cleavage sites are spatially separated in type IIS restriction enzymes, essentially any 
desired 5’-overhang sequence can be generated. Moreover, because the correct ligation 
products lack the enzyme recognition site and cannot be recut, the cleavage and ligation 
can be carried out in the same reaction mixture in a single step. To construct a TALE 
central repeat domain to recognize a desired target site, each individual repeat must be 
flanked by the type IIS restriction sites at both 5’- and 3’-ends. Restriction endonuclease 
digestion removes the flanking restriction sites and generates unique terminal overhangs. 
The overhangs are designed so that each repeat ligates specifically to another repeat with 
a compatible overhang. Thus, the 3’-end of first repeat can only ligate to the 5’-end of the 
second repeat, the 3’-end of the second repeat can only ligate to the 5’-end of the third 
repeat and so on. Therefore, the position of each repeat within the TALE central repeat 
domain is defined exclusively by the given overlap. For the first round of Golden Gate 
reaction, 6-10 repeats are cloned into an intermediate plasmid. The second round of 
Golden Gate reaction assembles the TALE repeat arrays of each intermediate plasmid 
into the final backbone plasmid and makes the complete TALE central repeat domain 
fused with FokI or other functional protein domains (Figure 1.6B). To increase the  
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Figure 1.6. Schematic of the strategies for the assembly of TALE repeat arrays. (A) The REAL 
strategy based on hierarchical ligations (107). (B) The Golden Gate cloning-based strategy (74). Each 
repeat unit is flanked by the recognition sites of a type IIS restriction endonuclease (black triangles). 
The first round of Golden Gate reaction assembles multiple TALE repeat units in a single step. The 
second round of Golden Gate reaction relies on the recognition site of a different type IIS restriction 
enzyme (pink triangles), which assembles the complete TALE genes from pre-assembled repeat 
multimers. (C) The FLASH assembly method based on solid-phase ligation (85). Ligations are carried 
out iteratively on a streptavidin-coated magnetic bead (brown circle), which contains an immobilized 
biotinylated DNA double-strand adaptor (green box). The final ligation product is released from the 
solid phase by restriction digestion and subcloned into the final backbone vector. 
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assembly efficiency, the lacZ gene and the toxic ccdB gene are introduced for blue/white 
screening and selection, respectively. With the help of preassembled TALE repeat 
tetramers and trimers, a single-step Golden Gate strategy has been developed to generate 
TALENs that recognize 15 bp target sites within two days (69). Due to its ease of use and 
public availability, Golden Gate assembly provides a convenient means to construct 
TALENs for academic laboratories.  
For industrial scale synthesis, development of a solid-phase ligation strategy has 
facilitated the cloning of TALE genes in a high-throughput and cost-effective manner 
(85,90,123). The solid-phase strategy assembles TALE repeat units on a streptavidin-
coated magnetic bead that contains an immobilized biotinylated DNA double-strand 
adaptor with a restriction endonuclease site on one end. Ligation of TALE repeat units is 
unidirectional and iterative. In each cycle, newly added TALE repeat units are ligated to 
the immobilized DNA fragments and subsequent washing steps remove undesired 
products. The cycle is continued until an array of the desired length is assembled. The 
final ligation product is then released from the solid phase by restriction digestion and 
subcloned into the final backbone vector (Figure 1.6C). With this strategy, TALE repeat 
units are assembled on solid-phase rather than in solution, thereby avoiding the need for 
gel isolation, purification or analysis of intermediate plasmids. With 376 archived 
plasmids encoding TALE repeats as tetramers, trimers, dimers and monomers, the fast 
ligation-based automatable solid-phase high-throughput (FLASH) system enables 
assembly of 96 TALE genes in less than one day. With automation, FLASH can make 
sequence-verified TALE expression plasmids for <$100 each, including the cost of labor 
(85). Instead of using a pre-assembled plasmid library, iterative capped assembly (ICA) 
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builds full-length arrays from individual TALE repeat monomers (123). Introduction of 
capping oligonucleotides eliminates incomplete ligation and monomer self-ligation, 
which are essential for the production of pure full-length TALE repeat arrays. With 
automation, ICA enables efficient assembly of TALE genes bearing up to 21 repeats 
followed by ligation into an expression plasmid within three hours. Wang and coworkers 
performed solid-phase ligation on a chip, which allows the synthesis of >100 TALE 
genes bearing 16 or 20 repeats in three days (90).  
Recently, a ligation-independent cloning (LIC) technique has been developed for 
high-throughput assembly of TALE genes (87). Compared with Golden Gate cloning, 
LIC relies on much longer (10-30 bp) nonpalindromic overhangs to anneal with the 
overhangs of other fragments in a highly specific manner. The long overhangs are 
generated by the controllable 3’-exonuclease activity of T4 DNA polymerase. Because 
the fragments’ long overlaps do not dissociate during transformation, the annealed 
products can be directly transformed into Escherichia coli without prior ligation step and 
ligated through bacterial ligases. Because of its high fidelity, LIC circumvents agar-based 
single-colony picking step, which allows growth of cells directly in polyclonal cultures 
after transformation. Using 64 repeat dimer-containing plasmids, LIC allows generation 
of correctly assembled TALE genes bearing 18.5 repeat units in three days through a 
hierarchical, two step assembly process. In addition, a comprehensive 5-mer TALE 
repeat unit fragment library composed of 3072 plasmids was created, which enables 
automated assembly of >600 TALE genes bearing 15.5 repeat units in one day.  
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1.4.4 Future perspectives 
The last three years witnessed the tremendous progress of the TALEN technology. The 
scaffold optimization isolated TALEN variants with high DNA cleavage efficiency, 
which is essential for targeted genome editing. The characterization of novel RVDs 
extended the DNA recognition code and helped to minimize off-target cleavage activity 
of TALENs by increasing guanine recognition specificity. Development of novel 
strategies for convenient and quick assembly of TALE repeat arrays enabled high-
throughput synthesis of TALENs and made TALEN technology accessible and affordable 
for any academic or industrial lab.  
Besides TALENs, there are other tools available for editing genomes. Meganucleases 
are natural DNA endnucleases with high activity and specificity, but it is difficult to tailor 
their DNA recognition specificities. It is relatively easier to engineer ZFNs to target 
custom-designed DNA sequences, but some of them suffer from requirement of intensive 
labor for construction and off-target effects (as reviewed in (132)). Recently, Clustered 
regularly interspaced short palindromic repeats (CRISPR)-mediated DNA cleavage has 
been applied for genome editing (133-138). This system can be reprogrammed readily 
using customized RNAs and enable multiplex genome engineering. However, the limited 
target specificity (14 bp) can cause off-target cleavage and the requirement for a 
protospacer adjacent motif (PAM) restricts its targeting range. Compared with these tools, 
TALENs have the advantage of high specificity and modularity, but there are limitations 
that remain to be addressed for their further improvement. The bulky size of TALENs 
might limit their broader applications, especially in the cases when efficient gene delivery 
cannot be achieved. Development of strategies for efficient delivery of TALEN genes 
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into cells would enable TALEN-mediated genome editing in more different organisms 
and cell types. In eukaryotic cells, DNA is packaged into chromatin. Therefore, 
chromosomal context and epigenetic modifications play a major role in the DNA 
accessibility of TALENs. The combination of epigenetic modification tools and TALEN 
technology could expand the range of target for TALEN-mediated genome modifications, 
which might be a potential area for future exploration. Unlike ZFNs, the off-target effects 
of TALENs have not been comprehensively characterized. Mussolino and coworkers 
carried out a side-by-side comparison between ZFNs and TALENs and found 
significantly reduced nuclease-associated cytotoxicities of TALENs (70). Ding and 
coworkers also reported minimal off-target-effects of TALENs using exome sequencing 
whole-genome sequencing at low coverage, but they still could not completely rule out 
TALEN off-target effects (69). Therefore, careful screening of the complete genome of 
TALEN-modified cells using deep sequencing analysis would be instructive for safe use 
of TALENs, especially for human clinical applications.  
Other than fusing with FokI to make DNA endonucleases, TALEs have been used to 
create novel chimeric proteins by fusing with other functional protein domains. TALE-
based transcription activators have been constructed to induce transcription of 
endogenous genes in plants (117) and human cells (74,119,127,139-141). By fusing with 
transcription repressor domains, TALEs have been used to generate artificial repressors 
for sequence-specific gene repression in bacteria (142), yeast (143), plants (144) and 
human cells (118,141). In addition, chimeric TALE recombinases (TALERs) have been 
constructed by fusing a hyperactivated catalytic domain from the DNA invertase Gin 
with a TALE central repeat domain (145). TALERs with optimized architecture 
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recombine DNA efficiently in bacterial and mammalian cells, providing an alternative 
approach for targeted genome editing. It would be interesting to combine TALE central 
repeat arrays with other different functional domains for many different applications in 
the future. For example, a TALE combined with a ligand-binding domain can be applied 
for high-throughput drug screening; a TALE combined with a DNA methyltransferase 
can be used for targeted DNA modification; a TALE combined with a histone 
deacetylase can be used for specific chromatin modification; a TALE combined with a 
cytosine deaminase can be applied for endogenous targeted mutagenesis, etc.  
Thanks to simplicity in design, convenience in construction and high success rates 
across species, TALEN technology has received much attention since its invention. 
Although challenges and obstacles remain, TALEN technology will continue to be an 
important topic for future research and development and benefit both basic and applied 
biological sciences.  
 
1.5 Project overview 
My thesis research focuses on the design, construction, optimization and application of 
TALENs as an efficient tool for genome engineering. Because the wild-type TALEs are 
transcription activators for bacterial infection of host plants, their sequences other than 
the DNA binding domain can be detrimental to the nuclease activity once fused with the 
FokI DNA cleavage domain. To maximize TALEN efficiency, protein engineering 
strategies including scaffold optimization and directed evolution have been utilized in 
yeast cells. A high-throughput screening of a linker library identified a novel TALEN 
architecture that can cleave the DNA target as a monomer. To demonstrate their 
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applications in human therapy, I applied the optimized TALENs for use in the treatment 
of sickle cell disease. TALEN-mediated genome editing enabled the correction of the 
disease-causing gene in induced pluripotent stem cells isolated from a patient.  
Chapter 2 describes scaffold optimization of TALENs for use in treatment of sickle 
cell disease. By using a yeast reporter system, a systematic study was carried out to 
optimize TALEN architecture for maximal in vivo cleavage efficiency. In contrast to the 
previous reports, the engineered TALENs were capable of recognizing and cleaving 
target binding sites preceded by A, C or G. More importantly, the optimized TALENs 
efficiently cleaved a target sequence within the human β-globin (HBB) gene associated 
with sickle cell disease and increased the efficiency of targeted gene repair by >1000-fold 
in human cells. In addition, these TALENs showed no detectable cytotoxicity. These 
results demonstrate the potential of optimized TALENs as a powerful genome editing 
tool for therapeutic applications. 
Chapter 3 reports the seamless gene correction of the sickle cell disease mutation in 
human induced pluripotent stem cells using TALENs. The TALENs I have engineered 
are highly specific and generate minimal off-target effects. In combination with piggyBac 
transposon, TALEN-mediated gene targeting leaves no residual ectopic sequences at the 
site of correction and the corrected stem cells retain full pluripotency and a normal 
karyotype. This study demonstrates an important first step of using TALENs for the 
treatment of genetic diseases, which represents a significant advance toward cell and 
gene therapies.  
Chapter 4 reports the development of a TALEN variant, SunnyTALEN, with >2.5-
fold improved genome editing efficacy in human cells. A high-throughput screening 
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system has been constructed in yeast cells in order to improve TALEN efficiency through 
directed evolution. After multiple rounds of mutagenesis and screening, 14 TALEN 
mutants were isolated with improved activity either in yeast or human cells, among which 
SunnyTALEN shows highest activity for human genome editing. The corresponding 
scaffold increases the rate of genetic modification at all the 13 tested loci of human 
genome and is compatible with heterodimer TALEN architectures. This enhanced and 
high-efficiency TALEN variant represents a novel second-generation TALEN system and 
has great potential for biological and therapeutic applications. 
Finally, Chapter 5 provides preliminary results of the development and 
characterization of a novel TALEN architecture, single-chain TALEN (scTALEN). 
Compared with the conventional TALEN scaffold, scTALEN has two FokI DNA 
cleavage domains which are linked by a polypeptide linker. The appropriate linker was 
isolated from a polypeptide linker library from high-throughput screening. Instead of 
forming a heterodimer, the scTALEN we identified can cleave the DNA substrate as a 
monomer, with the formation of a catalytic active intra-molecular FokI dimer. The 
corresponding scTALEN has moderate in vivo activity in both yeast and human cells. 
Compared with the conventional TALEN architecture, scTALEN has only half the 
protein size, which significantly decreases the gene delivery payload, especially for 
certain cell types such as primary human cells with low DNA or RNA delivery efficiency.  
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CHAPTER 2. SCAFFOLD OPTIMIZATION OF TALENS 
FOR USE IN TREATMENT OF SICKLE CELL DISEASE 
 
2.1. Introduction 
Sickle cell disease (SCD) is one of the most prevalent autosomal recessive disorders 
worldwide, with which approximately 250,000 infants are born each year (1). The 
homozygous mutation causing SCD is a single substitution (from A to T) in the codon for 
amino acid 6 on the human β-globin (HBB) gene. The replacement of glutamate by valine 
causes the body to produce an abnormal hemoglobin protein that tends to aggregate, 
making the red blood cells to become stiff and develop a sickle form. These sickle red 
blood cells can block blood vessels, thus reducing blood flow to many parts of the body 
that results in tissue and organ damage (reviewed by (2)). Ex vivo gene therapy by gene 
addition has proven to be an effective method to cure SCD in mouse models (3,4). 
However, these studies utilize viral vectors that could lead to a toxic immunological 
response (5). In addition, random insertion of foreign DNA fragments into human 
chromosomes may result in disruption of essential genes, thus causing unpredictable side 
effects (e.g., carcinogenesis) (6).  
Targeted gene correction is considered a promising strategy to cure SCD with 
minimal side effects because it can directly correct the mutation on the chromosome, thus 
preserving temporal and tissue-specific expression of the impaired HBB gene (7). 
Targeted gene correction involves the homologous recombination (HR) of chromosomal 
DNA sequences with exogenous DNA sequences to provide a precise method to 
systematically edit mammalian genomes (8). The rates of recombination in mammalian 
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cells typically fall in the range of 10
-6−10-5 events/cell/generation (9), which is an 
inherent limitation of this technique. However, chromosomal double strand breaks 
(DSBs) at a desired chromosomal locus can stimulate HR by upwards of 1000 fold to 
facilitate gene targeting (see Chapter 1).  
Zinc finger nucleases (ZFNs) show promise in improving the efficiency of gene 
targeting by generating DSBs at preselected sites on the chromosome (10,11). ZFNs are 
artificial DNA nucleases constructed by fusing the custom-designed zinc finger domain 
with the non-specific DNA cleavage domain of the FokI type IIS restriction 
endonucleases. Although the ZFN technology has been successfully applied to genome 
editing in many organisms including human cell lines (12), generating a sequence-
specific ZFN with novel specificity and high affinity remains an overwhelming challenge 
(13,14). Moreover, the lack of specificity of the zinc finger domains may lead to 
recognition of off-target sites, causing undesired genomic instability (15), which hampers 
its application in gene targeting based gene therapy.  
Transcription activator-like (TAL) effector nucleases (TALENs) are a new class of 
artificial nucleases that recognize long, specific DNA sequences (as reviewed in (16)). 
TALENs utilize the central repeat domain of TAL effectors (TALEs) as the DNA 
recognition module and the FokI catalytic domain as the DNA cleavage module. TALEs 
bind their target sites through a central repeat domain consisting of a varying number of 
repeat units of 33-35 amino acids. Each repeat is largely identical except for two highly 
variable amino acids at positions 12 and 13, referred to as the repeat variable di-residues 
(RVDs). Each repeat recognizes a single nucleotide, and the recognition specificity is 
determined by the RVDs (e.g., NI recognizes A, HD recognizes C, NG or HG recognizes 
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T, and NN recognizes G or A). The DNA recognition code provides a one-to-one 
correspondence between the array of amino acid repeats and the nucleotide sequence of 
the DNA target (17). This simple DNA recognition code and its modular nature make 
TALEs an ideal platform for constructing custom-designed artificial DNA nucleases.  
In this chapter, we sought to optimize TALEN scaffolds for use in treatment of SCD. 
By using a yeast based reporter system, we maximized the in vivo cleavage efficiency of 
TALENs by varying the N- and C-terminal extensions flanking the central repeat domain 
and the spacer length between each effector binding element (EBE) of the DNA 
substrates. In addition, we discovered that some TALEN architectures are capable of 
recognizing “unnatural” EBEs not preceded by a 5’-T. We constructed a pair of custom-
designed TALENs to recognize a target sequence within the HBB gene locus. This pair of 
TALENs with the optimized configurations allowed for efficient cleavage at the desired 
site and enhanced the HR rate by >1000-fold with no detectable cytotoxicity. This work 
describes the first example of engineered TALENs capable of recognizing and cleaving a 
human disease-associated gene. Such TALENs represent a promising approach to correct 
disease-causing point mutations in situ and serve as a powerful genome editing tool in 
gene therapy.  
 
2.2. Results 
2.2.1. Construction and optimization of TALENs 
AvrXa10 is a TALE from Xanthomonas oryzae pv. oryzae (18) containing a central 
region of 15.5 repeat units, with the last half repeat containing only the first 20 residues 
of other repeats. All of the reported TALEs require the first nucleotide of the binding site  
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N-terminal extension C-terminal extension
Central repeat units FokI cleavage domain
CN
B
0  1  2  3  4  5  6  7  8  9  10 11 12 13 14 15 15.5
AvrXa10 RVDs NI HG NI H* NI NI NN HD NI HD NN HG NS N* HD N*
AvrXa10 box T  A  T  A  T  A  A  G  C  A  C  G  T  A  T  C  T
A
5’-ATTTATATAAGCACGTATCTNNNNNNNNNNNNNTAAAGATACGTGCTTATATATAA
3’-TAAATATATTCGTGCATAGANNNNNNNNNNNNNATTTCTATGCACGAATATATATT
C
 
Figure 2.1. Structure and sequence of TALEN. (A) RVDs of the 15.5 repeat units of AvrXa10 with its 
DNA target sequence shown below. An asterisk indicates a deletion at residue 13. (B) Schematic of 
TALEN. N, N-terminus; C, C-terminus. (C) Palindromic target sites (PTSs) of TALEN-AvrXa10 are 
composed of two AvrXa10 EBEs (underlined) in an inverted orientation on different DNA strands, 
separated by a spacer (boxed) harboring an in-frame TAA stop codon (shaded in grey). TALEN-
AvrXa10 functions as a homodimer.  
 
to be preceded by a 5’-T at position 0 (17), meaning that the 15.5 repeats recognize a 17 
bp EBE (Figure 2.1A). We created an AvrXa10 based TALEN by fusing the central 
repeat domain of AvrXa10 with the FokI cleavage domain (Figure 2.1B). Since FokI 
dimerization is required for efficient DNA cleavage (19), two AvrXa10 EBE sites were 
placed in a tail-to-tail orientation separated by a spacer of varying lengths (6-32 bp), 
herein referred to as palindromic target sites (PTSs, Figure 2.1C). 
To determine the in vivo cleavage efficiency of a TALEN, we established a yeast 
reporter system adapted from a previously reported single strand annealing assay (20). 
The reporter plasmid contains a divided lacZ gene in which a duplicated 100 bp portion  
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GAL1p lac acZ ADH1t
GAL1p lac
acZ ADH1t
GAL1p lacZ ADH1t
Target site
Cleavage
Single strand annealing
 
Figure 2.2. Schematic of the yeast reporter system. Details are provided in the text. Recovered lacZ 
gene was shown in dotted box.  
 
of the LacZ coding region has been created. The two truncated lacZ DNA fragments are 
separated by a PTS containing an in-frame stop codon between the two EBE sites. Once 
the DSB between the two lacZ fragments is executed, the 100 bp direct DNA repeats will 
undergo HR and thus reconstitute a complete and functional lacZ gene (Figure 2.2). The 
β-GAL activity was used to quantify the HR rate, which correlates to the in vivo activity 
of the TALENs. Homing endonuclease I-CreI served as an internal control. 
The DNA fragment of the AvrXa10-encoding gene digested by StuI and AatII 
encompasses the coding sequence for the central repeat domain, 50 amino acids 
upstream, and 31 amino acids downstream, with the FokI catalytic domain fused to create 
a minimal TALEN (referred to as N0-C0, Figure 2.3). No activity was observed for N0-
C0 targeting any given DNA substrate (Figure 2.4 and Table 2.1). Since the N-terminal  
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MDPIRSRTPSPARELLPGPQPDRVQPTADRGGAPPAGGPLDGLPARRTMSRTRLPSPPA
▲N4(+287)
PSPAFSAGSFSDLLRQFDPSLLDTSLLDSMPAVGTPHTAAAPAECDEVQSGLRAADDPP
▲N3(+207)
PTVRVAVTAARPPRAKPAPRRRAAQPSDASPAAQVDLRTLGYSQQQQEKIKPKVRSTVA
▲N2(+135) ▲N1(+125)
QHHEALVGHGFTHAHIVALSQHPAALGTVAVTYQDIIRALPEATHEDIVGVGKQWSGAR
ALEALLTEAGELRGPPLQLDTGQLLKIAKRGGVTAVEAVHAWRNALTGAPLN
▲N0(+50)
------------------- Central Repeat Domain -----------------
LTPDQVVAIASNGGKQALESIVAQLSRPDPALAALTNDHLVALACLGGRPALDAVKKGL
▲C0(+31)
PHAPELIRRINRRIPERTSHRVADLAHVVRVLGFFQSHSHPAQAFDDAMTQFGMSRHGL
▲C1(+63)
AQLFRRVGVTELEARYGTLPPASQRWDRILQASGMKRAKPSPTSAQTPDQASLHAYYKD
▲C2(+117)
DDDKKGRPSPMHEGDQTRASSRKRSRSDRAVTGPSTQQSFEVRVPEQQDALHLPLSWRV
▲C3(+163)                            ▲C4(+200)
KRPRTRIGGGLPDPGTPIAADLAASSTVMWEQDAAPFAGAADDFPAFNEEELAWLMELL
PQSGSVGGTI
▲C5(+286)
 
Figure 2.3. The N- and C-terminal amino acid sequences of TALE AvrXa10. Positions of N- and C-
terminal extensions of all TALEN variants are shown and the values indicate the distance from the N- 
or C-terminus to the central repeat units. 
 
sequence of a TALE is important for its DNA binding (21), we set out to add additional 
N-terminal extensions from AvrXa10 to the N0-C0 scaffold to achieve DNA cleavage 
with high efficiency. The N1-C0 construct bearing a 125 amino acid N-terminal 
extension showed robust nuclease activity against PTSs with 10-16 bp spacers, with the 
cleavage efficiency over 2-fold compared to I-CreI. The N2-C0 and N3-C0 variants with 
longer N-terminal extensions remained active in cleaving PTSs with 10-16 bp spacers, 
and showed increased nuclease activity for longer DNA substrates, such as PTSs with a 
24 bp or a 32 bp spacer. The N4-C0 construct harboring the full length N-terminus from 
vrXa10 did not further increase activity toward PTSs with 10-16 bp spacers but showed  
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Figure 2.4. Nuclease activity of TALEN-AvrXa10 variants bearing N- and C-terminal extensions 
against target sites with the indicated spacers. TALEN scaffolds were indicated by the truncated N- 
and C-terminal positions as shown in Figure 2.3. Dot area indicates the relative β-GAL activity and 
represents the average of at least three independent experiments. “EBE” indicates that the cleavage 
target contains just one monomer binding site. The numeric values are shown in Table 2.1.  
 
reduced activity against PTSs with a 24 bp spacer or a 32 bp spacer.  
To further enhance the nuclease activity of the TALENs, we sought to add extra C-
terminal extensions on the N3-C0 variant, which showed the highest DNA cleavage 
efficiency for all the tested substrates. The N3-C1 variant containing a 63 amino acid C-
terminal extension cleaved longer DNA substrates (24 and 32 bp spacers) with >3-fold 
increased efficiency compared with N3-C0 variant, which allowed the TALEN to target 
PTSs in a moderately wide range (14-32 bp). We reasoned that a longer linker between  
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Table 2.1. Relative β-GAL activity of TALEN-AvrXa10 variants bearing N- and C-terminal 
extensions against target sites with the indicated spacers. The activity of I-CreI was normalized to 1. 
Values represent the average (± standard deviation) of at least three independent experiments. “EBE” 
indicates that the cleavage target contains just one monomer binding site.  
 EBE 6bp 8bp 10bp 12bp 14bp 15bp 16bp 24bp 32bp 
N0-C0 ND ND ND ND ND ND ND ND ND ND 
N1-C0 ND ND ND 1.7 ± 0.4 2.7 ± 0.7 2.3 ± 0.2 2.4 ± 0.4 2.6 ± 0.2 0.2 ± 0.0 ND 
N2-C0 ND ND ND 2.1 ± 0.2 2.8 ± 0.1 2.5 ± 0.1 2.3 ± 0.6 3.2 ± 0.2 0.6 ± 0.1 0.2 ± 0.0 
N3-C0 ND ND ND 2.7 ± 0.7 2.6 ± 0.7 2.2 ± 0.4 3.0 ± 0.4 3.1 ± 0.4 0.9 ± 0.2 0.3 ± 0.1 
N4-C0 ND ND ND 2.4 ± 0.2 3.0 ± 0.1 1.9 ± 0.4 2.7 ± 0.3 2.2 ± 0.5 0.4 ± 0.2 0.2 ± 0.0 
N3-C1 ND ND ND ND 0.1 ± 0.0 1.6 ± 0.3 2.9 ± 0.7 3.1 ± 0.8 3.1 ± 0.5 3.1 ± 0.3 
N3-C2 ND ND ND ND ND 0.5 ± 0.1 0.7 ± 0.5 2.1 ± 0.8 2.3 ± 0.5 1.9 ± 0.2 
N3-C3 ND ND ND ND ND ND 0.1 ± 0.0 0.8 ± 0.2 0.6 ± 0.1 0.3 ± 0.1 
N3-C4 ND ND ND ND ND ND 0.1 ± 0.0 1.5 ± 0.4 0.6 ± 0.0 0.4 ± 0.0 
N3-C5 ND ND ND ND ND 0.1 ± 0.0 0.2 ± 0.0 0.5 ± 0.4 1.6 ± 0.1 1.5 ± 0.6 
   ND: no detectable activity 
 
the TALE repeat units and the FokI cleavage domain may allow greater flexibility for the 
nuclease domain to cut close to or away from the ends of the EBE. However, additional 
extended C-terminal segments as shown in the N3-C2, N3-C3, N3-C4 and N3-C5 
variants led to reduced nuclease activity. Compared to N3-C0, longer C-terminal 
extensions abolished the nuclease activity against PTSs with 10 bp and 12 bp spacers, 
indicating that longer protein linkers require longer spacers to accommodate the 
additional length of the peptide.  
Taken together, TALENs harboring a short C-terminal extension (31 amino acids) 
require at least a 125 amino acid N-terminal fragment (as in the N1-C0 variant) to allow 
for efficient DNA cleavage against PTSs with 10-16 bp spacers, while the N3-C1 and 
N3-C2 variants with longer C-terminal extensions are capable of cleaving PTSs with 
longer spacers. Furthermore, none of the TALEN variants are able to cleave single EBE  
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Figure 2.5. Schematic of the mammalian gene targeting system. Details are provided in the text. 
Recovered EGFP gene was shown in dotted box.  
 
site or PTSs with 6 bp and 8 bp spacers, indicating an optimal range of spacer lengths 
(10-32 bp) between the two EBE sites is essential for efficient TALEN cleavage as a 
homodimer.  
 
2.2.2. Custom-designed TALENs stimulated gene targeting in human cells 
After demonstrating efficient DNA cleavage by engineered TALENs in yeast, we next 
sought to show that TALENs can produce a chromosomal DSB and modify the human 
genome. With a modified The enhanced green fluorescence protein (EGFP) gene 
conversion system (22), we were able to rapidly and quantitatively gauge the potential of 
TALEN-driven genome editing (Figure 2.5). The EGFP gene was divided into two  
64 
A
5’-TCACTAGCAACCTCAAACAGACACCATGGTGCATCTGACTCCTGTGGAGAAGTCTGCCGTTACT
M  V  H  L  T  P  V  E  K  S  A  V T     
3’-AGTGATCGTTGGAGTTTGTCTGTGGTACCACGTAGACTGAGGACACCTCTTCAGACGGCAATGA
HBB gene locus
C
TALEN-HBB-L
0  1  2  3  4  5  6  7  8  9  10 11 12 13 14 15 16 17 18 19 20 21 21.5
NI NN HD NI NI HD HD HG HD NI NI NI HD NI NN NI HD NI HD HD NI N*
T  A  G  C  A  A  C  C  T  C  A  A  A  C  A  G  A  C  A  C  C  A T
TALEN-HBB-R
0  1  2  3  4  5  6  7  8  9  10 11 12 13 14 15 16 17 18 18.5
NI NI HD NN NN HD NI NN NI HD HG HG HD HG HD HD NI HD NI
T  A  A  C  G  G  C  A  G  A  C  T  T  C  T  C  C  A  C  A
B
HBB-L site
HBB-R site
PE
E
G
F
P
-10
2
10
0
10
2
10
3
10
4
10
5
-10
2
10
1
10
3
10
4
10
5
PE
E
G
F
P
-10
1
10
2
10
3
10
4
10
5
-10
1
10
2
10
3
10
4
10
5
PE
E
G
F
P
-10
2
10
0
10
2
10
3
10
4
10
5
-10
2
10
1
10
3
10
4
10
5
PE
E
G
F
P
-10
1
10
2
10
3
10
4
10
5
-10
1
10
2
10
3
10
4
10
5
PE
E
G
F
P
-10
2
-10
1
10
2
10
3
10
4
10
5
-10
1
10
2
10
3
10
4
10
5
PE
E
G
F
P
-10
1
10
2
10
3
10
4
10
5
-10
1
10
2
10
3
10
4
10
5G
F
P
Autofluorescence
N1-C0
0.1±0.0 %
N0-C0
＜ 5×10-5
pCMV5
＜ 5×10-5
N3-C1
4.9±0.9 %
N4-C0
3.4±0.5 %
N3-C0
4.8±1.0 %
E
G
F
P
E
G
F
P
E
G
F
P
E
G
F
P
E
G
F
P
E
G
F
P
E
G
F
P
E
G
F
P
E
G
F
P
E
G
F
P
E
G
F
P
E
G
F
P
E
G
F
P
E
G
F
P
E
G
F
P
E
G
F
P
E
G
F
P
E
G
F
P
G
F
P
G
F
P
 
Figure 2.6. Custom-designed TALENs stimulated gene targeting in human cells. (A) Sequence of the 
HBB gene locus containing the single mutation (from A to T) causing SCD (shaded in grey) and the 
two user-defined TALEN binding sites (underlined). Amino acid sequence of β-globin is shown 
between the two DNA strands. (B) RVDs of the two custom-designed TALENs with their DNA target 
sequences shown below. An asterisk indicates a deletion at residue 13. (C) Representative flow 
cytometry plots of gene targeting. GFP-positive cells were quantitated in gate as depicted. 
Autofluorescence was measured using phycoerythrin-fluorescence channel. Empty vector pCMV5 
served as negative control. The values represent the average (± standard deviation) of the gene 
targeting rates from at least three independent experiments. 
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truncated and non-functional fragments by insertion of the TALEN target site in the 
middle of the gene, which was stably integrated into the genome of Hela cells. To 
perform the assay, the expression plasmids carrying a pair of TALEN genes were co-
transfected into the reporter cell line together with the donor plasmid bearing a promoter-
less and non-functional EGFP gene, which served as a template for repairing 
chromosomal DSB. Site-specific cleavage of the EGFP reporter gene by the TALEN pair 
will promote homology-dependent gene conversion, generating GFP-positive cells that 
can be quantified by flow cytometry.  
Based on the above results of TALEN architecture optimization and guidelines for 
TALEN site selection (23), we constructed a pair of custom-designed TALENs (referred 
to as TALEN-HBB-L and TALEN-HBB-R) as a heterodimer to target the disease-
causing mutational HBB gene locus (Figure 2.6A & B). The two target sites were 
separated by 15 bp. Cells that were transfected with an empty vector (pCMV5) or a 
minimal TALEN (N0-C0) had low autofluorescence or background recombination 
frequencies (< 5×10
-5
) (Figure 2.6C). Introduction of custom-designed TALENs with the 
N3-C0 or N3-C1 configuration converted 4.8% or 4.9% of the reporter cells to GFP-
positive respectively, stimulating the gene targeting rate by over 1000-fold. This result is 
on par with or better than the reported ZFNs tested using a similar reporter system, which 
converted 2-5% cells to GFP-positive (22,24). The N4-C0 configuration had less activity 
compared with N3-C0 and N3-C1, converting 3.4% of the reporter cells to GFP-positive. 
Surprisingly, the N1-C0 construct showed only 0.1% gene targeting rate, even though 
this configuration was efficient in cleaving palindromic sites in the yeast reporter system. 
Western blot analysis indicated that the TALEN-HBB-L construct with the N1-C0  
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Figure 2.7. Western blot analysis for the expression of TALEN variants. (A) Expression level of 
TALEN-HBB-L with different configurations. (B) Expression level of TALEN-HBB-R with different 
configurations. All the TALEN variants contained a FLAG tag at the N-terminus. α-tubulin was used 
as an internal control.  
 
configuration did not express well in human cells (Figure 2.7A), which may partially 
explain the lack of activity of this variant. On the other hand, all the tested TALEN-HBB-
R variants including the N1-C0 variant exhibited good expression levels (Figure 2.7B). 
Based on the gene targeting system discussed above, we analyzed each TALEN’s 
cleavage activity as a homodimer (Figure 2.8 and Figure 2.9). TALEN-HBB-L with the 
N1-C0 configuration exhibited little activity (0.4%) against the HBB-L palindromic site 
partially due to a low expression level, which is consistent with the activity as a 
heterodimer. However, the low GFP signal (0.5%) from TALEN-HBB-R with the N1-C0 
configuration indicated its low DNA cleavage activity, because it was expressed well in 
human cells. Similar to a heterodimer, each TALEN monomer bearing the N3-C0, N4-C0 
or N3-C1 configuration allowed for efficient cleavage as a homodimer, exhibiting >2% 
gene targeting rate. Taken together, the TALEN pairs we created with at least 207 amino 
acid N-terminal segment were capable of recognizing and cleaving preselected sites on 
the HBB gene locus efficiently. 
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5’-TGTAGCAACCTCAAACAGACACCATACTGATCTAGGACTAATGGTGTCTGTTTGAGGTTGCTAGT
3’-ACATCGTTGGAGTTTGTCTGTGGTATGACTAGATCCTGATTACCACAGACAAACTCCAACGATCA
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Figure 2.8. Activity of TALEN-HBB-L variants as a homodimer in a mammanlian gene targeting 
system. (A) Sequence of the HBB-L palindromic site with two HBB-L sites (underlined) in a tail-to-
tail orientation separated by a 15 bp spacer. (B) Representative flow cytometry plots of gene targeting. 
GFP-positive cells were quantitated in gate as depicted. Autofluorescence was measured using 
phycoerythrin-fluorescence channel. Hela cells with an EGFP reporter gene integrated into the 
genome were co-transfected with the expression vectors of TALEN-HBB-L variants and an EGFP 
donor as the DNA repair template. Empty vector pCMV5 served as negative control. The values 
represent the average (± standard deviation) of gene targeting rates from at least three independent 
experiments. 
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Figure 2.9. Activity of TALEN-HBB-R variants as a homodimer in a mammanlian gene targeting 
system. (A) Sequence of the HBB-R palindromic site with two HBB-R sites (underlined) in a tail-to-
tail orientation separated by a 15 bp spacer. (B) Representative flow cytometry plots of gene targeting. 
GFP-positive cells were quantitated in gate as depicted. Autofluorescence was measured using 
phycoerythrin-fluorescence channel. Hela cells with an EGFP reporter gene integrated into the 
genome were co-transfected with the expression vectors of TALEN-HBB-R variants and an EGFP 
donor as the DNA repair template. Empty vector pCMV5 served as negative control. The values 
represent the average (± standard deviation) of gene targeting rates at least three independent 
experiments. 
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Figure 2.10. Nuclease-associated cytotoxicity of TALENs. The columns denote the percentage of γ-
H2AX positive cells either transfected with artificial DNA nucleases or treated using etoposide with 
indicated concentration. Error bars indicate standard deviation from the average of at least three 
independent experiments. *, statistically significant increase of toxicity as compared to empty vector 
pCMV5 (P < 0.001).  
 
2.2.3. Custom-designed TALENs caused no detectable cytotoxicity 
The DNA binding specificity is a major determinant of cytotoxicity for ZFNs (25). Since 
the novel TALEN pair we designed recognizes a 43 bp long DNA recognition sequence, 
we postulated that it might not cause significant cytotoxicity due to its high specificity, 
even though there is some degeneracy in RVD recognition (i.e. NN can recognize G as 
well as A) (26). To assess the nuclease-associated toxicity, we monitored the intracellular 
level of γ-H2AX, which is the H2AX histone phosphorylated on serine 139 as a reaction 
on a chromosomal DSB (27). HEK293 cells displayed an average γ-H2AX level similar 
to the background (pCMV5 control) after being transfected with the TALEN pairs under 
the same conditions used to induce recombination in the gene targeting assay (Figure 
2.10). In contrast, when we transfected the cells with a reported toxic ZFN (28) or treated 
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the cells with etoposide (an anti-cancer agent that causes DNA DSBs (29)) for 2 h, 
significantly higher levels of H2AX phosphorylation were detected. Therefore, the 
engineered TALENs caused little, if any, cytotoxicity in human cells, demonstrating their 
high specificity.  
 
2.2.4. Targeting “unnatural” TALE sites 
Naturally occurring TALE recognition sites are uniformly preceded by a 5’-T (17); 
therefore, all of the previously reported TALENs were designed to target DNA sequences 
bearing a T at position 0. To test whether a preceding T is an essential requirement for 
efficient cleavage by TALENs, we selected five TALEN-AvrXa10 variants to measure 
their nuclease activities towards “unnatural” TALE sites with a preceding A, C or G 
using the yeast reporter system. The spacer length between each monomer binding site 
was fixed to be 16 bp, allowing for efficient cleavage for all the tested TALEN variants 
(Figure 2.4). As shown in Figure 2.11, the N2-C0 and N3-C0 constructs harboring short 
C-terminal extensions exhibited moderate nuclease activity against unnatural PTSs (0.5-1 
fold efficiency compared with I-CreI), which is still significantly lower than that towards 
the natural PTS with a T at position 0. The N4-C0 construct with a full length N-terminal 
segment displayed slightly reduced DNA cleavage efficiency towards all the tested 
substrates. The N3-C1 construct with additional C-terminal extension compared with the 
N3-C0 construct showed much higher cleavage efficiency against unnatural substrates. 
The N3-C1 construct cleaved PTSs bearing a preceding A, C or G with an efficiency 
similar to that for natural PTS with a preceding T. The extended 63 amino acid peptide 
linker between the DNA binding domain and the FokI cleavage domain in the N3-C1  
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Figure 2.11. Cleavage efficiency of TALEN-AvrXa10 variants targeting unnatural TALE substrates. 
Two EBE sites preceded with A, C, G or T separated by a 16 bp spacer were used as DNA substrates. 
I-CreI served as an internal control and the nuclease activity was normalized to 1. The columns denote 
the relative β-GAL activity and represent the average of at least three independent experiments. Error 
bars indicate standard deviation. * indicates significantly decreased activity (P<0.001) compared to 
the 5’-T preceded substrate. 
 
construct makes the TALEN less selective in terms of the 5’ preceding nucleotide. 
Longer C-terminal extension in the N3-C2 construct reduced the nuclease activity, but 
still exhibited less selectivity for a 5’-T. The decreased selectivity for the preceding 
nucleotide exhibited by the N3-C1 scaffold provides more flexibility in choosing 
endogenous target loci for genome editing when designing TALENs.  
 
2.3. Discussion 
In this study, we constructed ten TALEN variants and determined the optimal range of 
spacer lengths between the two EBE sites for each variant to allow for efficient DNA 
cleavage. The original TALENs were constructed by fusing the FokI catalytic domain 
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with full length TALEs (30-32). Since the naturally occurring TALEs are transcription 
activators from a plant bacterial pathogen, their N-terminal segment contains signal 
peptides responsible for protein translocation and C-terminal segment harbors nuclei 
localization signals and transcription activator domain (33). These redundant fragments 
can be detrimental to the TALENs nuclease activity. Therefore, TALEN scaffold needs to 
be optimized to achieve efficient cleavage. Previously, Miller et al. (26) truncated the 
first 152 N-terminal residues from TALE and produced a set of TALENs with different 
C-terminal truncations to maximize nuclease activity. Their variants with 28 amino acid 
or 63 amino acid C-terminal extensions exhibited highest DNA cleavage efficiency, 
which are similar to our N3-C0 and N3-C1 constructs, respectively. We found that N3-
C1 construct bearing 63 residues displayed efficient cleavage against DNA substrates 
with long spacers (16-32 bp), while Miller et al. did not observe this activity, which may 
be due to the shorter N-terminal segment in their TALEN variants. Even though they 
reported undetectable nuclease activity of TALEN with 93 amino acid C-terminal 
fragment, we observed efficient cleavage using N3-C4 and N3-C5 variants against DNA 
substrates with longer spacers, which is in agreement with the original study on TALENs 
bearing full length TALE C-terminus. More recently, Mussolino et al. (34) reported the 
most active configuration was a TALEN bearing 153 amino acid N-terminal segment and 
17 or 47 amino acid C-terminal segment, cleaving target sites with 12-15 bp spacer. 
However, their in vivo reporter system relied on the disappearance of GFP signal, in 
which the binding of TALENs to the target sites without cleavage may generate false 
positive signals (e.g., some of their TALEN variants exhibited positive result targeting 
single EBE site). Because the different TALEN activities in the above mentioned reports 
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were determined using different reporter systems, it is difficult to compare their results 
directly with ours. However, our systematic study clearly identifies two optimized 
TALEN scaffolds, with N3-C0 variant preferring PTSs with shorter (10-16 bp) spacers 
and N3-C1 variant preferring PTSs with longer (14-32 bp) spacers. This indicates that our 
optimized TALEN architectures have a moderately wide optimal range of spacer length 
between each TALEN monomer binding site, which allows for more flexibility with the 
choice of recognition sites in gene targeting study. 
The single mutation in HBB gene causes sickle cell disease, against which there is no 
adequate long-term treatment. Gene-insertion based gene therapy has been reported to be 
effective in mouse model by introduction of an antisickling HBB gene copy (3,4). 
However, immunogenicity and insertional mutagenesis caused by integrating viral 
vectors are still under safety concerns, which limit the wide application of this 
technology. Therefore, it is tempting to correct the mutational HBB gene in situ. In this 
study, we constructed a pair of TALENs that were able to recognize a user-defined 
sequence within HBB gene locus and stimulated gene targeting rate by over 1000-fold 
without detectable cytotoxicity. The TALENs with N3-C0 and N3-C1 scaffolds displayed 
highest cleavage efficiency, which is consistent with our result from yeast reporter 
system. To be noticed, N1-C0 variant exhibited high nuclease activity against PTS with 
15bp spacer in the yeast reporter system but showed little activity in the human gene 
targeting system, even though Western blot analysis indicated its good expression level. 
The inconsistency may be due to the difference between episomal cleavage in our yeast 
reporter system and chromosomal cleavage in the more complex genome in human cells. 
Taken together, our optimized TALENs with N3-C0 or N3-C1 scaffold exhibited robust 
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nuclease activity and low cytotoxicity in human cells, which can serve as a powerful tool 
for gene repair in gene therapy.  
A 5’-T preceding the TALE EBE sites was believed to be essential for TALE 
function (17), which, based on our study, turned out not to be the case for TALE 
nucleases. All the tested TALEN variants exhibited good nuclease activity against 
unnatural DNA substrate (0.5-1 fold efficiency compared with I-CreI); even though 
TALENs variants with short C-terminal extension still preferred to cleave natural 
TALEN recognition site. Interestingly, N3-C1 TALEN variant was capable of cleaving 
unnatural DNA substrates preceded by 5’-A, C or G with similar efficiency compared 
with that for natural TALE site. However, the longer C-terminal extension in N3-C1 
variant is at the 3’-end of the EBE, which is physically distant from the 5’-end of target 
site. We reasoned that the presence of a leucine zipper-like heptad repeats closely linked 
to the TALE central repeat units (35) may increase the DNA binding affinity of the 
central repeat domain and thus make the 5’-T interaction less of a requirement. More 
detailed structural studies will be needed to elucidate the protein-DNA interface of 
TALENs and their corresponding DNA substrates in order to solve this uncertainty. Our 
result indicates that the requirement for a 5’-T can be mitigated using certain scaffolds, 
thus allowing greater flexibility in choosing desired target site in genome editing 
endeavors. 
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2.4. Materials and methods 
2.4.1. Materials 
Phusion DNA polymerase, T4 DNA ligase, T4 polynucleotide kinase, antarctic 
phosphatase, and restriction endonucleases were purchased from New England Biolabs 
(Beverly, MA). QIAprep Spin Plasmid Miniprep Kit, QIAquick Gel Extraction Kit, and 
QIAquick PCR Purification Kit were obtained from Qiagen (Valencia, CA). 
Oligonucleotide primers were obtained from Integrated DNA Technologies (Coralville, 
IA). All the other reagents unless specified were obtained from Sigma-Aldrich (St Louis, 
MO). 
 
2.4.2. Yeast reporter system 
The yeast reporter system was constructed based on a single strand annealing assay with 
slight modifications (20). The lacZ gene was divided into two truncated and non-
functional copies by insertion of a palindromic target site consisting of two AvrXa10 
EBEs in a tail-to-tail orientation with various spacers. The two separated lacZ fragments 
sharing a 100 bp homologous region were PCR amplified separately, digested with AvrII 
and XbaI respectively and ligated overnight at 16 °C. The ligation product was 
subsequently digested with a combination of AvrII and XbaI and the 3.3 kb non-cut 
fragment was gel purified. The lacZ reporter gene was then cloned into the pRS414 
plasmid in between the GAL1 promoter and the ADH1 terminator, whose expression was 
induced by adding 2% galactose in the culture medium.  
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2.4.3. Construction of TALEN expression vectors  
The DNA sequence encoding the nonspecific DNA cleavage domain of FokI restriction 
endonuclease was PCR-amplified from pST1374 (plasmid 13426; Addgene, Cambridge, 
MA). The PCR product was inserted into pET28a(+) vector (EMD, Madison, WI) 
through NdeI and SalI recognition sites to yield plasmid pET28a-G4S-FokI. The DNA 
sequence encoding the central repeat DNA binding domain of TALE AvrXa10 was 
isolated from 0.7% agarose gel after digestion of the plasmid pAS202 (kindly provided 
by Dr. Frank F. White from Kansas State University, Manhattan, KS) using restriction 
enzymes StuI and AatII. The DNA fragment after gel extraction was cloned into the StuI 
and AatII sites of plasmid pET28a-G4S-FokI to make pET28a-TALEN-Xa10. The DNA 
sequences encoding the N-terminal extensions of the AvrXa10 protein with varying 
length were PCR-amplified from pAS202. The PCR products were digested with NdeI 
and StuI and cloned into the large fragment of the pET28a-TALEN-Xa10 vector digested 
with the same enzymes. The DNA sequences encoding the C-terminal extensions of the 
AvrXa10 protein with varying length were PCR-amplified using the same template and 
cloned into the AatII and AflII sites of the plasmid pET28a-TALEN-Xa10. The gene 
encoding TALEN-Xa10 with different configurations were subcloned into pRS415 
plasmid through the NdeI and SalI sites in between the GAL10 promoter and the ADH2 
terminator. The expression of TALENs in Saccharomyces cerevisiae was induced by 
adding 2% galactose in the cultural medium.  
The DNA sequences encoding the custom-designed TALE central repeat domains 
targeting the specific sequence within the HBB gene locus were synthesized by DNA2.0, 
Inc (Menlo Park, CA). The synthesized DNA sequences were codon optimized to 
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increase the protein expression level and reduce the repetitiveness among amino acid 
repeats in the DNA binding domain to facilitate DNA cloning. The genes of custom-
designed TALENs with different N- and C-terminal extensions were first cloned into the 
pET28a(+) vector using the same strategy as described above. Next, the TALEN genes 
along with a FLAG tag sequence and a SV40 nucleus localization signal added to the N-
terminus were subcloned into the pCMV5 mammalian expression vector (36) through the 
KpnI and SalI sites. The expression of these constructs is under the control of the 
cytomegalovirus (CMV) promoter. 
To test the in vivo cleavage activity of TALENs in the yeast reporter system, both the 
pRS414 reporter plasmid and pRS415 expression plasmid were transformed into 
Saccharomyces cerevisiae HZ848 (MATα, ade2-1, ade3Δ22, Δura3, his3-11,15, trp1-1, 
leu2-3,112 and can1-100) using the LiAc/SS carrier DNA/PEG method (37). After 3-4 
days growth at 30 °C on plates containing synthetic complete medium lacking leucine 
and tryptophan (SC-Leu-Trp) with 2% glucose, three transformants were picked to grow 
in SC-Leu-Trp liquid medium with 2% galactose. After cultivation for 2 days at 30 °C, 
yeast cells were harvested by centrifugation and lysed by Y-PER yeast protein extraction 
reagent (Pierce, Rockford, IL). The β-galactosidase (β-GAL) enzyme activity was 
determined by the β-galactosidase enzyme system from Promega (Madison, WI) 
according to the manufacturer's instruction. For each sample, the β-GAL activity was 
measured as a function of time and normalized by total protein concentration determined 
using the BCA protein assay (Pierce, Rockford, IL). Homing endonuclease I-CreI (38) 
serves as an internal control and its activity was normalized to one.  
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2.4.4. Human gene targeting system 
EGFP gene was divided into two fragments by insertion of a preselected sequence from 
the HBB gene locus and an in-frame stop codon. The non-functional EGFP reporter gene 
was cloned into the pLNCX2 retroviral vector (BD Clontech, Palo Alto, CA) under the 
cytomegalovirus (CMV) promoter and stably integrated into the genome via retroviral 
transduction according to the manufacturer’s protocol. Transfected Hela cells were 
selected in 500 μg/ml G418 for two weeks. A donor plasmid was constructed by insertion 
of a promoter-less EGFP gene with the first 37 nucleotides missing into the pNEB193 
plasmid (New England Biolabs, Beverly, MA) through the HindIII and SalI sites. The 
donor plasmid provides a homologous DNA segment as a template for repairing the DSB 
in the EGFP reporter. Construction of TALEN expression vectors is described in the 
Supplementary Data.  
Reporter Hela cells were maintained in modified Eagle’s medium (MEM) 
supplemented with 10% Fetal Bovine Serum (FBS; Hyclone, Logan, UT). Cells were 
seeded in 12-well plates at a density of 1×10
5
 per well. After 24 hr, reporter cells were 
co-transfected with 333 ng of each TALEN expression plasmid and 333 ng of donor 
plasmid using FuGene HD transfection reagent (Promega, Madison, WI) under 
conditions specified by the manufacturer. The transfection efficiency was determined to 
be between 45% and 50%. Cells were trypsinized from their culturing plates 48h after 
transfection and resuspended in 200 μL  phosphate buffered saline (PBS) supplemented 
with 10 mM EDTA for flow cytometry analysis. 20,000 cells were analyzed by BD 
LSRII flow cytometer (BD Biosciences, San Jose, CA) to determine the percentage of 
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GFP-positive cells. The rate of gene targeting was determined by normalizing the 
percentage of GFP-positive cells to the transfection efficiency. 
 
2.4.5. Immunoblotting 
Hela cells in 12-well plates were harvested 24 h after transfection with TALEN variants. 
Cells were collected by centrifugation, washed with PBS and resuspended in 40 μL RIPA 
lysis buffer (Santa Cruz Biotechnology, Santa Cruz, CA) with SDS-PAGE loading dye. 
Proteins were resolved by 4-20% Mini-Protean TGX Precast Gel (Bio-Rad Laboratories, 
Hercules, CA), transferred onto a nitrocellulose membrane, blocked for 1 hr with Tris-
buffered saline/0.05% Tween 20 containing 5% nonfat milk, followed by incubation with 
anti-FLAG tag (1:500) and anti-α-tubulin (1:5000) antibodies at 4 °C overnight. After 
incubation with anti-mouse horseradish peroxidase-conjugated secondary antibody 
(1:25000; GeneScript, Piscataway, NJ) for 1 hr, bands were visualized using SuperSignal 
West Pico Chemiluminescent Substrate (Pierce, Rockford, IL).  
 
2.4.6. H2AX phosphorylation assay 
HEK293 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% FBS. Cells were seeded in 12-well plates (2×10
5 
/well) and 
transfected after 24 hr with 500 ng of each TALEN expression plasmid, 1 μg empty 
pCMV5 vector as a negative control or 1 μg reported toxic ZFN construct GZF3N 
(kindly provided by Dr. Toni Cathomen of Hannover Medical School, Hannover, 
Germany) as a positive control, respectively. After 48 h post transfection, cells were 
harvested, fixed, permeabilized, and stained using the H2AX phosphorylation assay kit 
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(Millipore, Watford, UK) according to the manufacturer’s protocol. Alternatively, cells 
were treated with dimethyl sulfoxide (DMSO), 2 μM and 10 μM etoposide in DMSO for 
2 hr before staining. Cells were then scanned in a flow cytometer to quantitate the 
number of cells staining positive for phosphorylated histone H2AX.  
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CHAPTER 3. SEAMLESS GENE CORRECTION OF 
SICKLE CELL DISEASE MUTATION IN HUMAN 
INDUCED PLURIPOTENT STEM CELLS USING TALENS 
 
3.1. Introduction 
Human induced pluripotent stem cells (hiPSCs) are genetically reprogrammed from adult 
somatic cells. Similar to human embryonic stem cells (hESCs), hiPSCs can propagate 
indefinitely in culture and differentiate to all somatic tissues (1). Disease-specific hiPSCs 
derived from patients have invaluable therapeutic applications such as studying disease 
mechanisms, screening effective drugs, and perhaps most importantly, treating diseases 
via cell replacement therapies (2,3). For the treatment of genetic disorders which are 
caused by genomic abnormalities, patient-derived hiPSCs can be corrected in culture and 
thus provide a renewable cell source for autologous transplantations, in which modified 
hiPSCs (or their differentiated progenies) can be transplanted back into the patient to 
restore normal cell functions (4).  
To correct genetic defects in hiPSCs, a gene-insertion based strategy has been 
developed in which viral vectors are used to carry a normal gene for the substitution of 
the defective endogenous counterpart (5). However, immunogenicity and insertional 
mutagenesis caused by integrating viral vectors are major safety concerns. Alternatively, 
the mutated gene can be corrected in situ by homologous recombination (HR), which not 
only circumvents the safety concerns but also ensures the corrected gene expressed in the 
natural genetic context and thus in the appropriate temporal and tissue-specific manner. 
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However, the low HR frequency (<10
-6
) in human stem cells prevents its wide application 
(6). 
To address this limitation, custom-designed DNA endonucleases such as zinc finger 
nucleases (ZFNs) and transcription activator-like (TAL) effector nucleases (TALENs) 
have been constructed to introduce a site-specific DNA double-strand break (DSB) on the 
chromosome and enhance HR frequency by >1000 fold (see Chapter 1). ZFNs have been 
successfully applied to induce HR-based gene correction in patient-derived hiPSCs (7-10). 
Yet the low specificity of the ZFNs can cause cleavage at off-target sites, resulting in 
undesired genomic instability (11,12). Moreover, the limited modularity of zinc finger 
domains makes it difficult for ZFNs to target many disease-causing genes. In contrast, 
TALENs represent a new class of artificial nucleases with high specificity and modularity 
(13,14). The central repeat domain of a TALEN consists of repeating units of 33-35 
amino acids. Each repeat recognizes a single nucleotide and the specificity is conferred 
by the highly variable di-residues at positions 12 and 13 (e.g. Asn-Ile recognizes A, His-
Asp recognizes C, Asn-Gly recognizes T, and Asn-Asn recognizes G and A) (15,16). The 
simple DNA recognition code and the modular nature make TALENs an ideal platform 
for use in targeted gene correction.  
To explore the potential therapeutic application of TALENs in hiPSC-based cell and 
gene therapies, we chose sickle cell disease (SCD) as a model system (see Chapter 2). 
SCD is the most common autosomal recessive disorder that affects more than 300 000 
individuals worldwide each year (17). A homozygous mutation (from A to T) in the sixth 
codon of the human β-globin (HBB) gene converts a glutamate to a valine, which 
generates abnormal β-globin proteins and results in malfunctional red blood cells (18). 
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The absence of an adequate long-term treatment makes hiPSCs-based cell replacement 
therapy highly attractive. In this study, we successfully applied TALENs to correct the 
SCD mutation in patient-derived hiPSCs. In combination with piggyBac transposon, 
TALEN-mediated gene correction left no residual ectopic sequences at the site of 
correction. Treated hiPSCs maintained the genomic integrity and the pluripotency. This 
study provides an important proof of principle that TALENs can be used in hiPSC-based 
cell and gene therapies. Similar strategies can be applied to correct other genetic 
disorders, which represents a significant advance in basic biomedical research and human 
clinical applications.  
 
3.2. Results 
3.2.1. Construction of a donor plasmid for HBB
S
 gene correction 
We constructed a pair of custom-designed TALENs to recognize the sickle HBB (HBB
S
) 
gene at the mutation site (Figure 2.6) (19). In order to correct the sickle mutation (E6V) 
of the HBB
S
 gene by TALEN-induced HR, we constructed a donor plasmid to provide an 
overall ~2.5 kb homology sequence carrying a wild-type HBB gene (HBB
A
) with GAG 
for codon six to substitute GTG (Figure 3.1). The donor plasmid also contains a 
piggyBac transposon, which is a mobile element that transposes efficiently in human 
stem cells (9). The piggyBac transposon carries a bifunctional fusion protein (puroΔtk) 
constitutively expressed under PGK promoter, in which puro (puromycin N-
acetyltransferase) is used for positive selection and Δtk (a truncated version of herpes 
simplex virus type 1 thymidine kinase) is used for negative selection (20). The PPGK-
puroΔtk cassette is flanked by two piggyBac terminal inverted repeats (PB5 and PB3)  
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Figure 3.1. Schematic overview depicting the strategy for the seamless correction of the HBB
S
 gene 
using TALENs and piggyBac transposon. (A) Sequence of the genomic HBB
S
 gene locus. Amino 
acids of the beginning part of human β
S
-globin protein are shown in ovals. The A to T substitution 
(bold letter) causes the E6V mutation (grey oval) in human β
S
-globin. The two TALEN recognition 
sites (underlined) are separated by a 15 bp spacer. The TALEN cleavage site and the integration site 
for piggyBac transposon (in frame) are indicated. (B) Schematic of the donor plasmid design and gene 
correction strategy. The donor plasmid comprises two homology arms and a piggyBac transposon 
(dotted).  
 
into the TTAA site to enable its subsequent excision. Expression of piggyBac transposase 
will excise the transposon seamlessly, without leaving any residual sequences. 
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Figure 3.2. Representative results of nested-PCR screening of puromycin-resistant colonies after 
TALEN-induced HR. Φ, genomic PCR product from untreated hiPSCs as a negative control; +, 
internal round of PCR product from the donor plasmid as a positive control; M, 1 kb DNA Ladder 
(New England Biolabs, Beverly, MA); *, genomic PCR product from correctly targeted hiPSC 
colonies.  
 
3.2.2. Seamless correction of the HBB
S
 gene in the SCD patient-derived hiPSCs  
To correct the HBB
S
 gene, we transfected SCD patient-derived hiPSCs carrying a 
homozygous E6V mutation with the TALEN-expression plasmids together with the 
donor plasmid. TALEN cleavage induced HR, which enabled the replacement of the 
chromosomal HBB
S
 gene with the episomal HBB
A
 gene and simultaneously integrated a 
piggyBac transposon carrying the drug-selectable cassette (Figure 3.1B). Puromycin-
resistant hiPSC colonies were picked and expanded for nested-PCR screening. We 
observed that >50% puromycin-resistant colonies were correctly targeted (Figure 3.2). 
To remove the drug-selectable cassette from the modified hiPSCs, the piggyBac 
transposase gene was transiently transfected to the cells. After negative selection under 
fialuridine, hiPSC colonies were picked and expanded. Genotyping was performed by 
genomic PCR followed by restriction digestion with Bsu36I, which cleaves the corrected  
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Figure 3.3. Seamless monoallelic gene correction of the HBB
S
 gene in SCD patient-derived hiPSCs. 
(A) Sequences of sickle (HBB
S
) and wild-type (HBB
A
) human β-globin gene. Amino acids from the 
beginning part of human β-globin protein are shown in ovals. The A to T substitution (bold letter) 
causes the E6V mutation (grey oval) of HBB
S
 gene, which abolishes a Bsu36I restriction site in HBB
A
 
gene. (B) Bsu36I analysis confirming the correction of the HBB
S
 gene. HEK293 cell line has both 
HBB
A
 alleles, which are sensitive to Bsu36I digestion. SCD patient-derived hiPSCs (SCD-hiPSC) 
have both HBB
S
 alleles, which are resistant to Bsu36I digestion. Corrected SCD-hiPSCs have one 
HBB
S
 allele and one HBB
A
 allele, as indicated by the double bands. (C) Sequence analysis showing 
the HBB gene locus of the untreated patient-derived hiPSCs and the gene-corrected hiPSCs. The ATG 
start codon is indicated by a black arrow. The nucleotide substitutions are highlighted by red frames. 
Y, double peaks of C and T; W, double peaks of A and T. 
 
(HBB
A
) but not the sickle (HBB
S
) gene (Figure 3.3A & B). Two out of 48 hiPSC 
colonies were sensitive to Bsu36I digestion, indicating the correction of the mutation on 
one allele (Figure 3.4). Sequencing of the genomic PCR products of the two corrected  
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Figure 3.4. Representative results of Bsu36I digestion screening of fialuridine-resistant hiPSC 
colonies after excision of the piggyBac transposon. Φ, analysis of the untreated hiPSCs as a negative 
control; M, 100 bp DNA Ladder (New England Biolabs); *, correct hiPSC colony with one HBB
S
 
allele corrected and the piggyBac transposon removed.  
 
hiPSC colonies confirmed that transposon excision did not leave any residual “scar”, 
demonstrating that one HBB
S
 gene in the SCD patient-derived hiPSCs was corrected 
seamlessly (Figure 3.3C). Two introduced silent mutations were observed as initially 
designed, confirming that the replacement was introduced by TALEN-mediated gene 
correction, and not by spontaneous reversion. 
 
3.2.3. Characterization of the gene-corrected hiPSCs 
The gene-corrected hiPSCs maintained pluripotency, as indicated by the uniform 
expression of pluripotency-specific marker proteins including OCT4, SOX2, SSEA4, 
TRA-1-60 and TRA-1-81 (Figure 3.5). To test pluripotency in vivo, the corrected hiPSCs 
were transplanted into severe combined immunodeficiency (SCID) mice and tumor 
formation was observed in 9-10 weeks. Histological examination showed that the tumor 
comprised cell types originating from all three developmental germ layers (Figure 3.6), 
including gland (endoderm), duct (endoderm), cartilage (mesoderm), blood vessel  
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Figure 3.5. Immunostaining analysis. The corrected hiPSCs display characteristic pluripotency 
markers including OCT4, SOX2, SSEA4, TRA-1-60 and TRA-1-81. Nuclei were stained with 
HOECHST.  
 
(mesoderm), white adipose tissue (mesoderm) and neural rosette (ectoderm). Those 
evidences indicate that TALEN-mediated genome editing did not alter the pluripotent 
state of the corrected hiPSCs.  
To monitor possible off-target events introduced by TALEN cleavage, we analyzed 
six genomic regions harboring the potential off-target cleavage sites (predicted by TAL 
Effector Nucleotide Targeter 2.0 (21)), including a highly similar sequence within the 
HBD gene that shares only four mismatches compared with the designed TALEN binding 
site (Table 3.1). Off-target activity was measured by SURVEYOR nuclease assay 
(Material and methods), which monitors the small insertions and deletions generated by  
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Figure 3.6. Teratoma formation and analysis of the corrected hiPSCs. Hematoxylin and eosin  
staining indicates in vivo differentiation of endodermal (gland and duct), ectodermal (neural rosette) 
and mesodermal (cartilage, blood vessel and white adipose tissue) structures.  
 
imprecise DNA repair from non-homologous end joining (NHEJ) in response to TALEN 
cleavage. In contrast to HBB gene locus, within which exists three mismatches between 
the corrected (HBB
A
) and uncorrected (HBB
S
) genes, none of the other six analyzed sites 
were off-targeted (Figure 3.7A). In addition, karyotype analysis showed that the 
TALEN-mediated gene correction and piggyBac transposon excision processes 
maintained genomic integrity of the corrected hiPSCs without causing any unexpected 
chromosomal translocations and alterations (Figure 3.7B). These evidences indicate high 
specificity and safety of using TALENs and piggyBac transposon for targeted genome 
editing in patient-derived hiPSCs.  
 
 
94 
Table 3.1. Potential off-target sites of the custom-designed TALENs for the recognition of HBB
S
 gene. 
Bases differing from the left TALEN recognition site (underlined) and the right TALEN recognition 
site (bold) are highlighted. The possible off-target events within ZNF204P and CDH18 genes are 
generated by the formation of homodimer of the right TALEN.  
Featured 
Gene 
TALEN recognition sites Mismatch (bp) Spacer 
length (bp) Left Right Left Right 
HBB
S
 AGCAACCTCAAACAGACACCAT AACGGCAGACTTCTCCACA 0 0 15 
HBD AGCAACCTCAAACAGACACCAT GACAGCAGTCTTCTCCTCA 0 4 15 
HLF AGGGAACCCAAACAATCACCAT AACAGCAAAGCTCCCCAGA 6 6 14 
PTPRG AGCAACCTGAAACACTCCCACT TACAGAATACTTCTCAACT 6 6 16 
NSUN5 AAAAACCCCAAACCCACACCCA ACCAGTAGACCTCTGCACC 7 6 27 
ZNF204P AACTGAAGGCTTTTCCACA AACATCAGATAACTCAACA 4 6 29 
CDH18 CATATCACACTTTTCCACA CAAGCCACACTACACCACA 6 6 30 
 
3.3. Discussion 
Obtainable from adult somatic cells and capable of growing indefinitely and 
differentiating into all cell types, hiPSCs open up various novel avenues for basic 
biomedical research and human therapeutics. The ultimate promise of hiPSCs, although 
at a very early stage of development, is to treat diseases by cell replacement therapy. 
Patient-derived hiPSCs can provide a renewable autologous cell source for the treatment 
of degenerative diseases such as central nervous system injuries, myocardial infarction, 
and diabetes (22). Moreover, if the disease-causing mutations can be repaired in vitro, 
corrected hiPSCs can serve as regenerative medicines for the treatment of genetic 
disorders such as SCD and β-thalassemia. Toward this end, a proof-of-principle has been 
established in a SCD mouse model, including derivation of disease-specific mouse 
induced pluripotent stem cells (miPSCs) from adult somatic cells, repair of genetic 
mutations by HR-mediated gene targeting, differentiation of corrected miPSCs into 
therapeutic relevant cells, and subsequent autologous transplantation (4). However,  
95 
 
Figure 3.7. Analysis of off-target effects. (A) SURVEOR nuclease analysis of the potential off-target 
sites. The HBB
A/S
 site has three mismatches between corrected (HBB
A
) and uncorrected (HBB
S
) genes, 
which is sensitive to SURVEOR nuclease cleavage. All of the six potential off-target sites (sequences 
are shown in Table 3.1) are resistant to SURVEOR nuclease cleavage. *, product of SURVEOR 
nuclease cleavage. (B) Karyotyping analysis of the corrected hiPSCs.  
 
similar approaches are not applicable to human gene therapy because of the low HR rate 
in human cells, making the gene correction step a major obstacle.  
To address this limitation, rare-cutting DNA endonucleases such as ZFNs and 
TALENs have been constructed to introduce a chromosomal DSB close to the mutation 
site. Subsequent DSB repair by HR can increase the gene targeting rate significantly (23-
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25). ZFNs have been applied to correct disease-causing mutations in hiPSCs derived 
from patients with SCD (7,10), Parkinson’s disease (8), and α1-antitrypsin deficiency (9). 
However, the lack of specificity of zinc finger domains raises safety concerns about 
potential off-target cleavage, which might lead to undesired mutations and chromosomal 
aberrations (11,12). In addition, zinc finger domains have limited modularity due to the 
context-dependent DNA-binding effects. Recently, TALENs have rapidly emerged as an 
alternative to ZFNs and have been widely applied for genome editing in many different 
organisms and cell types (19,26-38). The modular nature of the TALE central repeat 
domains enables researchers to tailor DNA recognition specificity with ease and target 
essentially any desired DNA sequence (15,16). Moreover, TALENs exhibit minimal off-
target effects as determined by exome sequencing and whole-genome sequencing (37), 
indicating their potential utility for human therapeutics. In this study, we sought to 
explore the therapeutic potential of TALENs in hiPSCs-based cell and gene therapies. 
We successfully applied TALENs to correct the SCD mutation in patient-derived hiPSCs. 
The corrected hiPSCs maintain their pluripotent state. TALEN-mediated gene correction 
does not introduce detectable off-target events or chromosomal alterations.  
Although the chromosomal DSBs introduced by custom-designed DNA 
endonucleases can significantly stimulate HR, the overall gene targeting rate is still low, 
which makes it necessary to introduce a drug-selectable cassette into the chromosome for 
the isolation of targeted colonies. To remove the unwanted drug-selection cassette after 
positive selection, the Cre/loxP recombination system has been frequently used, which 
leaves a 34 bp loxP sequence at the site of excision (7,10,35,39,40). However, the small 
ectopic sequence has the potential to silence the gene expression of the targeted allele (10) 
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or interfere with transcription regulatory elements of adjacent genes (41). To address this 
limitation, we inserted the drug-selectable cassette into a piggyBac transposon, which 
enables the removal of the selection cassette efficiently in hiPSCs without leaving any 
remnant sequences (9). After TALEN-mediated gene correction and drug selection, 
transient expression of piggyBac transposase excised the drug-selectable cassette without 
leaving any residual “scar” in the corrected gene. The combination of TALEN and 
piggyBac technology enabled us to correct the SCD mutation in patient-derived hiPSCs 
in a seamless manner.  
Because robust protocols for differentiating hiPSCs into mature, enucleated red blood 
cells in vitro have not been established, functional data demonstrating the recovery of the 
gene-corrected red blood cells cannot be generated in this study. In addition, a 
reproducible in vivo model is needed to test the efficacy and safety of using the gene-
corrected hiPSCs as a renewable autologous cell source for the treatment of SCD patients 
(10,42,43). Although challenges and barriers remain, our study demonstrates an 
important first step of using TALEN technology and piggBac transposon to correct the 
disease-causing mutation in situ in a seamless manner, which represents a significant 
advance toward hiPSC-based cell and gene therapies.  
 
3.4. Materials and methods 
3.4.1. Cell culture 
SCD patient-derived hiPSCs with a homozygous E6V mutation were kindly provided by 
Dr. Marius Wernig from Stanford University (Stanford, CA). Cultures were maintained 
under feeder-free culture conditions on 6-well plates coated with Matrigel Basement  
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Figure 3.8. Plasmid map of the donor plasmid. 
 
Membrane Matrix (BD Biosciences, Bedford, MA) in mTeSR1 medium (StemCell 
Technologies, Vancouver, Canada). Subculture was performed every 5 to 7 days by 
washing hiPSCs with DMEM/F12 medium, incubating with 1 mg/mL dispase (StemCell 
Technologies) for 7 min at 37 °C, washing with DMEM/F12 medium, detaching with a 
cell scraper, breaking down into small clumps and plating onto a new Matrigel-coated 
plate.  
 
3.4.2. Plasmid construction 
Human expression plasmids for the TALEN pair targeting the HBB
S
 gene have been 
described previously (19). The donor plasmid pMCS-HBB-PB:PGKpuroΔtk (Figure 3.8) 
was constructed by replacing the 5’- and 3’- homology arms of pMCS-AAT-
PB:PGKpuroΔtk (9) (kindly provided by Dr. Allan Bradley from Wellcome Trust Sanger 
Institute, Cambridge, UK) with homology sequences of the HBB
A
 gene. The 5’- and 3’- 
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HBB homology arms were amplified by PCR from the genomic DNA of HEK293 cells. 
The primers AscI-HBB-5’-for (5’-act gac ggc gcg cct att ctt agt gga cta gag g-3’, AscI 
site shown in italic) and PB5-HBB-5’-rev (5’-gca tgc gtc aat ttt acg cag act atc ttt cta ggg 
tta agg ttg cta gtg aac aca gtt-3’) amplified the 1.0 kbp 5’- HBB homology arm. The 
primers PB3-HBB-3’ (5’-ttt aac gta cgt cac aat atg att atc ttt cta ggg tta aac aga cac cat 
ggt gca tct-3’) and PacI-HBB-3’-rev (5’-act gac tta att aat gga cag caa gaa agc gag c-3’, 
PacI site shown in italic) amplified the 1.5 kbp 3’- HBB homology arm. The two terminal 
inverted repeats (PB5 and PB3) of piggyBac transposon were amplified by PCR from 
pMCS-AAT-PB:PGKpuroΔtk. PB5 was amplified by primers HBB-5’-PB5-for (5’-ctt 
aca ttt gct tct gac aca act gtg ttc act agc aac ctt aac cct aga aag ata gtc-3’) and NheI-PB5-
rev (5’-act tgt gct agc att cta gtt gat atc tat aac-3’, NheI site shown in italic). PB3 was 
amplified by primers NotI-PB3-for (5’-gct aga gcg gcc gca ctc gag ata tct aga c-3’, NotI 
site shown in italic) and HBB-3’-PB3-rev (5’-cag act tct cct cag gag tca gat gca cca tgg 
tgt ctg ttt aac cct aga aag ata atc-3’). 5’-HBB homology arm was combined with PB5 by 
overlap extension-PCR (OE-PCR) (44) and inserted into AscI and NheI sites of pMCS-
AAT-PB:PGKpuroΔtk to form pMCS-Intermediate. 3’-HBB homology arm was 
combined with PB3 by OE-PCR and inserted into NotI and PacI sites of pMCS-
Intermediate to form donor plasmid pMCS-HBB-PB:PGKpuroΔtk. 
 
3.4.3. TALEN-mediated genome editing of hiPSCs 
On day 0, SCD-hiPSCs were pre-treated with 2 μM of a Rho Kinase (ROCK) inhibitor 
(thiazovivin, BioVision, Milpitas, CA) for at least 1 hr prior to transfection. Cells were 
dissociated into single-cell suspension by washing with DMEM/F12, incubating with 
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accutase (StemCell Technologies) for 7 min at 37 °C, mixing with mTeSR1 medium 
followed by vigorous pipetting. 3 × 10
6
 cells were transfected with 2 μg of each TALEN-
encoding plasmid and 2 μg of donor plasmid by Amaxa nucleofection system using 
Human Stem Cell Nucleofector Kit 1 (Lonza, Cologne, Germany) according to the 
manufacturer’s instruction. The treated cells were plated onto one Matrigel-coated 100 
mm dish in mTeSR1 medium supplemented with 2 μM of thiazovivin for the first 24 hrs. 
On day 3, puromycin (Sigma, St. Louis, MO) selection at 0.5 μg/mL was started. 
Individual colonies were picked and expanded in one or two Matrigel-coated 24-well 
plates on day 13-17. On day 20-24, near-confluent cells in each well were harvested 
using accutase. One quarter of the cells was seeded onto a new Matrigel-coated 24-well 
plate and the rest of the cells were used for nested PCR analysis.  
 
3.4.4. Nested PCR of targeted integration 
Genomic DNA was extracted from hiPSCs using QuickExtract DNA Extraction Solution 
1.0 (EPICENTRE Biotechnologies, Madison, WI) according to the manufacturer’s 
instructions. The external round of PCR was carried out using primers Purotest-for-PB3 
(5’-ggc tcg aga tcc act agt tc-3’) and Purotest-rev-HBB3-long (5’-gat gct caa ggc cct tca 
ta-3’). The external round of PCR products were used as template for the internal round 
of PCR using primers Nested-for-HBB3 (5’-acg tgg atg aag ttg gtg gt-3’) and HBB-R (5’-
taa ggg tgg gaa aat aga cc-3’). Nested PCR products were then resolved on a 1.0% 
agarose gel.  
 
 
101 
3.4.5. Transposon excision in targeted hiPSCs 
On day 0, correctly targeted hiPSCs were pre-treated with 2 μM of thiazovivin for at least 
1 hr prior to transfection. Cells were dissociated into single-cell suspension as described 
earlier. 2 × 10
6
 cells were transfected with 4 μg of the hyperactive piggyBac transposase 
expression vector (pCMV-hyPBase (45), kindly provided by Dr. Allan Bradley) by 
Amaxa nucleofection system using Human Stem Cell Nucleofector Kit 1 according to the 
manufacturer’s instructions. The treated cells were plated onto one Matrigel-coated 100 
mm dish in mTeSR1 medium supplemented with 2 μM of thiazovivin for the first 24 hrs. 
On day 3, cells were dissociated into single-cell suspension and seeded to a new 
Matrigel-coated 100 mm dish at low density (~1000 cells/mL) in mTeSR1 medium 
containing 2 μM of thiazovivin and 0.25 μM of fialuridine (Santa Cruz Biotechnology, 
Santa Cruz, CA). On day 6, medium was changed to mTeSR1 medium supplemented 
with 2.5 μM of fialuridine, which was used for daily medium change until picking 
colonies. Individual colonies were picked and expanded in one or two Matrigel-coated 
24-well plates on day 16-20. On day 23-27, near-confluent cells in each well were 
harvested using accutase. One quarter of the cells was seeded onto a new Matrigel-coated 
24-well plate and the rest of the cells were used for Bsu36I analysis and sequencing.  
 
3.4.6. Bsu36I analysis and sequencing of genomic HBB locus 
Genomic DNA from corrected hiPSCs was amplified with primers HBB-F (5’-agg tac 
ggc tgt cat cac tt-3’) and HBB-R (5’-taa ggg tgg gaa aat aga cc-3’) under standard PCR 
conditions, which resulted in a 402 bp product. PCR products were purified by QIAquick 
Gel Extraction Kit (QIAGEN, Valencia, CA) and subjected to restriction digestion with  
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Table 3.2. Sequences of primers that are used to amplify the potential off-target sites for the 
SURVEYOR nuclease assay.  
Gene Primer sequences 
HBB 
Forward   5'-agg tac ggc tgt cat cac tt-3' 
Reverse   5'-taa ggg tgg gaa aat aga cc-3' 
HBD 
Forward   5'-agg gaa tag tgg aat gaa gg-3' 
Reverse   5'-aga cca cca gta atc tga gg-3' 
HLF 
Forward   5'-gtc ata tgt tga aag agg gc-3' 
Reverse   5'-aga cca ttc caa ata tag cag g-3' 
PTPRG 
Forward   5'-ctg tat gta tcc aac atc ata ctg-3' 
Reverse   5'-ctc tgc agt tct gtc aag ga-3' 
NSUN5 
Forward   5'-gca ctg gaa tgg cta aag ag-3' 
Reverse   5'-tag tag cgg aga cag taa gg-3' 
ZNF204P 
Forward   5'-gtc tgt cct ctg cct aaa gg-3' 
Reverse   5'-aac tca cac tgg aga gaa gc-3' 
CDH18 
Forward   5'-acc atc aga tct cct gag ac-3' 
Reverse   5'-taa gtc taa gtg cgc tca tg-3' 
 
Bsu36I (New England Biolabs, Beverly, MA) to detect the E6V mutation and 
subsequently separated on a 2% agarose gel. The E6V mutation of β-globin disrupts an 
existing Bsu36I restriction site, so that the digestion of the corrected allele results in two 
~200 bp fragments whereas the mutant allele results in one 402 bp fragment. The 
correction event was identified by sequencing of the 402 bp PCR amplicons using HBB-
F and HBB-R as sequencing primers.  
 
3.4.7. Off-target cleavage analysis 
Potential off-target cleavage sites were identified by TAL Effector Nucleotide Targeter 
2.0 using high score cutoff (21). DNA fragments (~400 bp) containing the potential off-
target sites were PCR-amplified from the genomic DNA extracted from hiPSCs using the 
primers described in Table 3.2. Gel-purified PCR products were reannealed slowly and 
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analyzed by SURVEYOR Mutation Detection Kits (Transgenomic, Omaha, NE) 
according to the manufacturer’s instructions. Off-target cleavage of TALENs can be 
repaired by NHEJ, which typically generates deletions and insertions. Therefore, 
genomic PCR products from TALEN-modified region are heterogeneous. After 
reannealing, DNA heteroduplexes can be cleaved by SURVEYOR nucleases, which 
indicates off-target cleavage of the TALENs. Because the potential off-target sites are 
designed to be in the center of the genomic PCR products (~400 bp), cleavage by 
SURVEYOR nucleases can generate two ~200 bp fragments. On the contrary, genomic 
PCR products from TALEN-unmodified regions are homogeneous, which are resistant to 
SURVEYOR nuclease. 
 
3.4.8. Immunostaining 
Expression of the five pluripotent markers including OCT4, SOX2, SSEA4, TRA-1-60 
and TRA-1-80 were analyzed by Human ES/iPS Cell Characterization Kit (Applied 
StemCell, Menlo Park, CA) according to the manufacturer’s instruction. HOECHST stain 
was used to stain nuclei. 
 
3.4.9. Karyotyping 
Karyotyping of the gene-corrected hiPSCs was carried out by Applied StemCell Inc. 
(Menlo Park, CA). 
 
3.4.10. Teratoma formation and analysis 
The gene-corrected hiPSCs were dissociated with dispase and triturated as small clumps 
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and injected into kidney capsule and testis sites (1.5-3×10
6
 cells per site) of three 6-week 
old male mice (Fox Chase SCIDR-beige from Charles River Laboratories, Wilmington, 
MA). Cells from a hiPSC line were injected into the same sites of one mouse as a positive 
control. Tumor formation was observed in the three mice and harvested at day 74 post 
injection. The tumor samples at the six sites were fixed in 10% formalin overnight, 
embedded in paraffin, cut into 5-μm serial sections, and analyzed by hematoxylin and 
eosin staining.  
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CHAPTER 4. DIRECTED EVOLUTION OF TALENS WITH 
IMPROVED GENOME EDITING EFFICACY 
 
4.1. Introduction 
Genetic modifications of human genomes have a wide range of applications such as 
investigating human biology, studying disease mechanisms and treating diseases via gene 
therapies (1,2). Although virus-based transgenesis can modify human genomes efficiently 
by introduction of exogenous genes, random integration of viral transgenes poses the risk 
of insertional mutagenesis and carcinogenesis (3,4). In contrast, targeted genome editing 
or engineering enables researchers to tailor the human genome in a precise manner. To 
achieve efficient genome editing in human cells, DNA double-strand breaks (DSBs) have 
to be introduced at the specific sites of the chromosome by custom-designed DNA 
endonucleases. Subsequent repair of the DSBs by non-homologous end joining (NHEJ) 
or homologous recombination can generate desired genomic modifications such as gene 
disruptions, gene deletions, gene insertions, gene replacements and chromosome 
rearrangements (see Chapter 1). 
Recently, transcription activator-like effector (TALE) nucleases (TALENs) have 
emerged as an efficient and versatile tool for genome editing by introduction of 
chromosomal DNA DSBs (5-7). TALENs are artificial DNA endonucleases composed of 
a TALE central repeat domain as the DNA recognition module and a non-specific FokI 
nuclease domain as the DNA cleavage module. The TALE central repeat domain 
comprises a series of tandem repeat units, each of which typically contains 34 residues. 
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Each repeat is used to recognize a single nucleotide and the DNA recognition specificity 
is determined by the highly variable residues at positions 12 and 13 (e.g. NI recognizes 
adenine, HD recognizes cytosine, NG recognizes thymine, NH recognizes guanine and 
NN recognizes guanine and adenine) (8-11). The simple DNA recognition code and the 
modular nature of the TALE central repeat units enable researchers to tailor DNA 
recognition specificity with ease and target essentially any desired DNA sequence. 
Therefore, TALENs have been widely applied for genome editing in various species (7). 
Due to their long recognition sequences (30-50 bp) and high DNA recognition specificity, 
TALENs exhibit minimal off-target effects in the context of complex human genomes 
(12-14), making them an ideal platform for human genome editing.  
First-generation TALEN scaffolds have been described with different N-terminal 
segments (NTSs) and C-terminal segments (CTSs) flanking the TALE central repeat 
domains (13-16). Some of them have been applied for generating human stem cell-based 
disease models (12) and treating human diseases (17,18), but their efficacy of modifying 
human genomes is limited in targeting certain loci (16,19). Specifically, only ~5% of 
cells can be converted into GFP-positive in the human cell reporter assay as shown in 
Chapter 2 and only 1 copy of the HBB
S
 gene can be corrected as shown in Chapter 3. 
Those evidences indicate a high-efficiency TALEN system in human cells is highly 
desirable for both scientific and therapeutic applications. Although a second-generation 
TALEN platform called GoldyTALEN has been reported with improved genome editing 
efficacy in zebrafish (20) and livestock (21), its efficacy in modifying human genomes 
has not been demonstrated. In this chapter, we report the development and application of 
a high-throughput screening system to improve TALEN activity through a directed  
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Table 4.1. Recognition sequences of TALENs. The TALE binding sites are highlighted.  
Target 
site 
Recognition sequence 
Spacer 
length (bp) 
AvrXa10 TATATAAGCACGTATCTTCTAGGATAGGACTAAAGATACGTGCTTATATA 16 
HBBS TAGCAACCTCAAACAGACACCATGGTGCATCTGACTCCTGTGGAGAAGTCTGCCGTTA 15 
ABL1 TACCTATTATTACTTTATGGGGCAGCAGCCTGGAAAAGTACTTGGGGACCAA 17 
APC TATGTACGCCTCCCTGGGCTCGGGTCCGGTCGCCCCTTTGCCCGCTTCTGTA 16 
BRCA2 TTAGACTTAGGTAAGTAATGCAATATGGTAGACTGGGGAGAACTACAAACTA 16 
CCND1 TGGAACACCAGCTCCTGTGCTGCGAAGTGGAAACCATCCGCCGCGCGTACCCCGA 16 
CCR5 TGCTGGTCATCCTCATCCTGATAAACTGCAAAAGGCTGAAGAGCATGACTGACA 15 
ERCC2 TCCGGCCGGCGCCATGAAGTGAGAAGGGGGCTGGGGGTCGCGCTCGCTA 16 
FH TGTACCGAGCACTTCGGCTCCTCGCGCGCTCGCGTCCCCTCGTGCGGGCTCCA 17 
MYC TGCTTAGACGCTGGATTTTTTTCGGGTAGTGGAAAACCAGGTAAGCACCGAA 16 
PTEN TCCCAGACATGACAGCCATCATCAAAGAGATCGTTAGCAGAAACAAAAGGA 16 
SDHC TGTTGCTGAGGTGACTTCAGTGGGACTGGGAGTTGGTGCCTGCGGCCCTCCGGA 16 
SS18 TGGTGACGGCGGCAACATGTCTGTGGCTTTCGCGGCCCCGAGGCAGCGAGGCA 17 
XPA TGGGCCAGAGATGGCGGCGGCCGACGGGGCTTTGCCGGAGGCGGCGGCTTTA 16 
 
evolution strategy. We successfully isolated a TALEN variant, SunnyTALEN, with 
significantly improved efficacy in modifying human genomes. We demonstrate that the 
corresponding TALEN scaffold is more active than the GoldyTALEN system in human 
cells and compatible with previously published obligate heterodimeric FokI nuclease 
domains. This novel second-generation TALEN system provides a general solution for 
efficient modifications of human genomes with low toxicities and has great potential in 
both basic and applied biological sciences.  
 
4.2. Results 
4.2.1. Development of a high-throughput screening system 
To improve the performance of the existing TALEN technology using directed evolution, 
we developed a high throughput screening system in Saccharomyces cerevisiae. This 
system employs an enhanced green fluorescent protein (eGFP)-based single-strand 
annealing reporter construct that is integrated into the yeast genome. The reporter 
construct contains a divided eGFP gene harboring two AvrXa10 TALE binding sites in a  
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Figure 4.1. Schematic of an eGFP-based single-strand annealing reporter system in yeast. ADH1p, 
promoter of the ADH1 gene; ADH1t, transcription terminator of the ADH1 gene; eGF, 5’-fragment of 
the eGFP gene; and GFP, 3’-fragment of the eGFP gene.  
 
tail-to-tail orientation (Figure 2.1C and Table 4.1). The DSB generated by the AvrXa10 
TALEN homodimer can induce single-strand annealing of the two truncated eGFP DNA 
fragments and reconstitute a complete and functional eGFP gene (Figure 4.1). Therefore, 
this system couples the enzymatic DNA cleavage activity with the fluorescent signal of 
host cells, and enables high-throughput screening of TALEN mutants with improved 
genome editing efficacy. The TALEN gene expression is under the control of a galactose-
inducible promoter, thus the selection pressure of directed evolution can be adjusted by 
galactose concentration in the growth medium and incubation time during induction 
(Figure 4.2).  
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Figure 4.2. Activities of the WT TALEN in the eGFP-based yeast screening system under different 
induction conditions.  
 
4.2.2. Directed evolution of TALENs with improved activity 
Using a TALEN scaffold bearing a 207 aa NTS and a 63 aa CTS (hereinafter referred to 
as WT) (14) as a template, we randomly mutagenized the sequences encoding the CTS 
and the FokI nuclease domain using error-prone PCR and constructed a library of 
mutants in vivo by gap repair homologous recombination in yeast (Figure 4.3). TALEN 
expression was induced by galactose and the eGFP-positive cells were collected by 
fluorescence-activated cell sorting (FACS). The sorted cells were pooled together and 
plasmids from the pool were isolated. The regions encoding the CTS and FokI nuclease 
domain of TALEN genes were PCR-amplified from the plasmids and subjected to 
another round of screening. This process was continued in an iterative fashion until the 
TALEN mutants with improved genome editing activity were enriched and identified 
(Figure 4.4). We gradually increased the selection stringency by decreasing the galactose 
concentration and induction time during the enrichment (Figure 4.5). After two rounds of  
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Figure 4.3. Strategy for the creation of a TALEN mutant library. (A) Schematic depicting random 
mutagenesis of the CTS and the FokI nuclease domain and assembly of the library of mutants through 
homologous recombination in yeast. GAL10p, promoter of GAL10 gene; ADH2t, transcription 
terminator of ADH2 gene; and CEN6, a centromere of yeast chromosome. LEU2 auxotrophic marker 
is used for selection of transformants in yeast. Asterisks indicate mutagenized CTS and FokI. (B) 
Sequence and numbering of the CTS and the FokI domain. The CTS is highlighted in magenta. The 
FokI domain is highlighted in orange.  
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Figure 4.4. Schematic representation of the directed evolution approach in yeast for isolating novel 
TALEN variants.  
 
 
Figure 4.5. Directed evolution of TALENs in the yeast screening system. The columns denote the 
percentage of eGFP-positive cells in each screening cycle and the induction of TALEN expression 
was performed in galactose (GAL)-containing medium for certain amounts of time. The arrows 
indicate the portions of cells that were collected by FACS and applied for the next cycle of screening.  
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Table 4.2. Nomenclature, sequence information and in vivo activities of TALEN variants. The residue 
numbering is indicated in Figure 4.3B. Silent mutations are shown in grey. Activities in yeast were 
measured when the TALEN expression was induced in the cultural medium containing 0.02% 
galactose for 4 h. Activities in human cells were measured in the modified surrogate reporter system 
(Figure 4.6) in a dose-limiting condition (32 ng transfected TALEN expression plasmids per 10
5
 
cells). The activity of WT was normalized to 1. Values represent the average (± standard deviation) of 
at least three independent experiments. 
Label Mutation 
Relative activity (fold of WT) 
yeast human cells 
WT  - 1.00 ± 0.11 1.00 ± 0.05 
Sharkey S35P, K58E  2.38 ± 0.23 1.01 ± 0.02 
Goldy
a
 L(-33)M, I(-16)V, P(-11)G  3.24 ± 0.15 0.80 ± 0.06 
S4C5 P(-11)T, H(-6)Q, V52I 3.49 ± 0.14 2.08 ± 0.10 
S4C9 P(-11)H, L182L, R186R  2.90 ± 0.32 2.26 ± 0.11 
S4C10 K58R, N144K 1.30 ± 0.10 0.40 ± 0.03 
S7C1 P(-11)R, I82I, H115H, N153K, L168L, L182L 4.40 ± 0.16 1.11 ± 0.03 
S7C6 P(-11)H 4.11 ± 0.23 2.26 ± 0.03 
S7C7 S5S, I175I, K176Q, L182L 2.83 ± 0.17 1.62 ± 0.08 
S7C10 K58E, I70I, L182L, E193V 1.76 ± 0.22 0.10 ± 0.01 
Sunny P(-11)H, S35P, K58E  4.13 ± 0.27 2.69 ± 0.43 
2S3C3 P(-11)H, S35P, K51E, K58E 7.26 ± 0.38 2.21 ± 0.14 
2S3C11 P(-11)H, S35P, K58E, A87A, F134Y 6.85 ± 0.42 0.91 ± 0.02 
2S3C12 L(-33)L, P(-11)H, L18L, S35P, K58E, K123N 4.91 ± 0.40 1.96 ± 0.09 
2S3C18 
P(-11)H, E(-10)K, L7L, S35P, K58E, I70M, 
P76L, V81V 
6.20 ± 0.57 1.69 ± 0.14 
2S6C1 P(-11)H, N34D, K58E 5.88 ± 0.56 1.10 ± 0.05 
2S8C6 P(-11)H, E(-10)K, S35P, K58E 5.67 ± 0.47 2.03 ± 0.19 
a 
GoldyTALEN has a shorter and mutated NTS compared with all the other TALENs. 
 
mutagenesis and evolution, fourteen TALEN mutants with improved activity were 
generated (Table 4.2). The most active mutant (2S3C3) has greater than sevenfold 
improvement in yeast genome modification compared to WT, whereas GoldyTALEN and 
the TALEN bearing a Sharkey domain (a FokI domain variant with S35P and K58E 
mutations) (22) only exhibit <3.5-fold increase compared to WT.  
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Figure 4.6. Schematic of a modified surrogate reporter system in Hela cells. CMVp, CMV promoter.  
 
4.2.3. Isolation and characterization of the SunnyTALEN scaffold 
To test the efficacy of the isolated TALEN mutants in human cells, we modified a 
surrogate reporter system (23) to rapidly and quantitatively gauge the potential of 
TALEN-driven genome editing (Figure 4.6). The reporter construct encoding a 
monomeric red fluorescent protein (mRFP)-eGFP fusion protein was stably integrated 
into the genome of Hela cells. A TALEN target site within sickle human β-globin (HBBS) 
gene locus (Table 4.1) (14) was inserted between the mRFP and eGFP genes, making the 
eGFP gene out of frame. In response to the TALEN-induced DSBs, certain insertions and 
deletions (indels) caused by NHEJ-mediated mutagenesis will make the eGFP gene in 
frame and restore eGFP function. Each TALEN mutant was under the control of a 
cytomegalovirus (CMV) promoter, and genome editing activity was measured by flow 
cytometry following transient expression. Although the TALEN bearing a Sharkey  
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Figure 4.7. Dose-response curve using titrations of different TALEN expression plasmids as tested in 
the modified surrogate reporter system in Hela cells. Error bars indicate standard deviation of three 
independent experiments.  
 
domain and GoldyTALEN showed similar or lower genome editing efficacy compared to 
WT, one TALEN mutant (referred to as SunnyTALEN) has >2.5-fold improvement 
compared to WT (Table 4.2). SunnyTALEN contains a single P(-11)H mutation on the 
CTS and a Sharkey domain. We performed titrations of the expression plasmids of 
different TALEN architectures at various amounts and obtained a dose-response curve 
(Figure 4.7). SunnyTALEN consistently yielded more eGFP-positive cells compared to 
the other TALEN variants. The P(-11)H mutation of SunnyTALEN serves as a major 
contributor to its improved efficacy without changing protein expression level. The S35P 
and K58E mutations on the Sharkey domain increase activity marginally, which can be 
explained by the increased protein solubility (Figure 4.8). The lower protein expression 
level of GoldyTALEN is consistent with its lower efficacy in human cells than WT. 
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Figure 4.8. Western blot analysis of TALEN variants in human cells. All the TALEN variants 
contained a FLAG tag at the N-terminus. α-Tubulin was used as a loading control. An asterisk 
indicates non-specific bands. 
 
4.2.4. Application of the SunnyTALEN scaffold for human genome editing 
To further explore the general applicability of the SunnyTALEN scaffold in modifying 
human genomes, we generated TALENs against 12 additional genomic loci of human 
embryonic kidney (HEK) 293 cells. Using the same TALE DNA binding domains in the 
SunnyTALEN scaffold, we observed increased rate of gene modification at all the 
targeted loci compared to WT, with the increased indels ranging from 4% to 33% in 
response to NHEJ-mediated mutagenesis (Figure 4.9). Sequencing analysis of the two 
targeted loci indicated that SunnyTALENs induced more small deletions than insertions 
(Figure 4.10), with the mutation signatures similar to the first-generation TALENs (24) 
and GoldyTALENs (20). We also explored whether the rates of TALEN-induced 
homologous recombination could be enhanced using an eGFP gene conversion assay 
(Figure 2.5 and Figure 4.11A) (14). In the linear range of the dose-response curve, we 
observed a >2-fold increase in homology-directed gene repair using the SunnyTALEN 
scaffold over WT (Figure 4.11B), which paralleled the increase observed in NHEJ-
mediated gene disruption levels (Figure 4.7).  
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Figure 4.9. Application of the SunnyTALEN scaffold for human genome editing. (A)The 
SunnyTALEN scaffold improved NHEJ-mediated gene disruptions at 12 genomic loci in HEK293 
cells. (B) Representative gel images of the SURVEYOR nuclease assay to determine the frequencies 
of TALEN-induced indels. 
 
To prevent the formation of unexpected cleavage-competent homodimers, obligate 
heterodimeric FokI domains have been used in TALENs to reduce off-target effects and 
cytotoxicities (25,26). To investigate the compatibility of the SunnyTALEN scaffold with 
the obligate heterodimeric FokI domains, we introduced the ELD:KKR FokI pair (ELD 
denotes Q103E, I116L and N113D mutations; KKR denotes E107K, I155K and H154R  
123 
BRCA2 
5’-TTAGACTTAGGTAAGTAATGCAATATGGTAGACTGGGGAGAACTACAAACTA-3’ 
 
Mutated sequences   
5’-TTAGACTTAGGTAAGTAATGCAAT----TAGACTGGGGAGAACTACAAACTA-3’ 
5’-TTAGACTTAGGTAAGTAATGCAAT--GGTAGACTGGGGAGAACTACAAACTA-3’ 
5’-TTAGACTTAGGTAAGTAATGCAA---------CTGGGGAGAACTACAAACTA-3’ 
5’-TTAGACTTAGGTAAGTAATGCAAT---G-AGACTGGGGAGAACTACAAACTA-3’ 
5’-TTAGACTTAGGTAAGTAATGCAATA---TAGACTGGGGAGAACTACAAACTA-3’  
5’-TTAGACTTAGGTAAGTAATGCAATA-----GACTGGGGAGAACTACAAACTA-3’ 
5’-TTAGACTTAGGTAAGTAATGCAAT---------TGGGGAGAACTACAAACTA-3’ 
 
SS18 
5’-TGGTGACGGCGGCAACATGTCTGTGGCTTTCGCGGCCCCGAGGCAGCGAGGCAAG-3’  
 
Mutated sequences 
5’-TGGTGACGGCGGCAA---------------------------------------G-3’ 
5’-TGGTGACGGCGGCAA----------G--TTCGCGGCCCCGAGGCAGCGAGGCAAG-3’ 
5’-TGGTGACGGCGGCAAC----------CTTTCGCGGCCCCGAGGCAGCGAGGCAAG-3’ 
5’-TGGTGACGGCGGCAACATGTCTGTG---TT-------CCGAGGCAGCGAGGCAAG-3’ 
5’-TGGTGACGGCGGC-----------------------CCCGAGGCAGCGAGGCAAG-3’ 
5’-TGGTGACGGCGGCAACATGTCTGTGGGGCTGCTGCTTTCGCGGCCCCGAGGCAGCGAGGCAAG-3’ 
Figure 4.10. Sequencing analysis of the mutagenesis generated by SunnyTALEN-induced NHEJ 
against BRCA2 and SS18 sites in HEK293 cells. TALEN binding sites are highlighted in yellow. 
Deleted nucleotides are shown in dashes. Inserted nucleotides are shown in red.  
 
mutations) (27) that preferentially heterodimerize into the SunnyTALEN scaffold and 
compared the genome editing efficacy with the WT counterpart in the modified surrogate 
reporter system (Figure 4.6). The pairwise analysis of these architectures showed that the 
TALEN heterodimers with SunnyTALEN scaffold had >4.4-fold improvement at 
stimulating mutagenesis compared to the WT TALEN heterodimers (Figure 4.12). None 
of the ELD:ELD or KKR:KKR TALEN dimers were observed to be cleavage-competent. 
To assess the nuclease-associated toxicity, we monitored the phosphorylation of histone 
H2AX (γ-H2AX), which rapidly responds to chromosomal DSBs and can be used to 
measure genome-wide DNA damage levels. Although the SunnyTALEN scaffold slightly  
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Figure 4.11. The SunnyTALEN platform enhanced the efficiency of homologous recombination in 
human cells. (A) Schematic of an eGFP gene conversion assay in Hela cells. (B) Dose-response curve 
using titrations of different TALEN expression plasmids as tested in the eGFP gene conversion assay. 
Error bars indicate standard deviation of three independent experiments. 
 
increased γ-H2AX level over WT, the introduction of the obligate heterodimeric FokI 
domains reduced γ-H2AX staining to the background level (Figure 4.13).  
 
4.3. Discussion 
In this study, we developed a powerful yeast-based screening system to improve TALEN 
activity. This system couples enzymatic DNA cleavage with GFP signal of yeast cells 
and enables directed evolution of TALENs with improved genome editing efficacy. The 
GFP-positive cells can be isolated by FACS, which enables high-throughput screening of  
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Figure 4.12. The SunnyTALEN scaffold is compatible with the obligate heterodimeric FokI nuclease 
domains. Activities were measured in the modified surrogate reporter system (Figure 4.6) in a dose-
limiting condition (32 ng transfected TALEN expression plasmids per 10
5
 cells). Error bars indicate 
standard deviation of three independent experiments. Empty vector pCMV5 served as a negative 
control.  
 
large libraries of mutants with single cell resolution and low false positive rate. Although 
applied here in enhancing TALEN activity, this system can be easily adapted to engineer 
other rare-cutting DNA endonucleases such as homing endonucleases (or meganucleases) 
(28), zinc finger nucleases (ZFNs) (29), and newly developed clustered regularly 
interspaced short palindromic repeats (CRISPR)-Cas system (30-34), for the purpose of 
increasing catalytic activities or altering DNA recognition specificities.  
In the SunnyTALEN scaffold, the P(-11)H mutation on the CTS plays a major role in 
activity improvement. Because structural information is not available to visualize that 
residue, we have built structural models of WT and SunnyTALEN scaffolds with 63 aa  
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Figure 4.13. Nuclease-associated cytotoxicities of TALENs. Low dose indicates 32 ng TALEN 
expression plasmids were transfected per 10
5
 cells. High dose indicates 256 ng TALEN expression 
plasmids were transfected per 10
5
 cells. A reported toxic zinc finger nuclease (GZF3N) served as a 
positive control (35). Error bars indicate standard deviation of three independent experiments. 
 
CTSs to study the molecular mechanism. Structural models indicate the substitution of a 
histidine for a proline introduces an additional hydrogen bond between the CTS of the 
SunnyTALEN scaffold and the DNA backbone, which might increase catalytic activity 
by positioning the FokI nuclease domain closer to the DNA substrate or to the FokI 
domain of the other TALEN monomer (Figure 4.14). More detailed structural studies 
will be needed to confirm this hypothesis. In addition to the isolation of a high-efficiency 
TALEN system, our directed evolution endeavor identified “hot spot” residues (e.g. P(-
11), E(-10), N34, S35, K51, K58, F134 and K176) that are critical for the catalytic 
activity or protein solubility of TALENs (Table 4.2), which provides an important insight 
for the further improvement of TALEN system by rational protein design or saturation 
mutagenesis.  
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Figure 4.14. Structural models of the WT and SunnyTALEN scaffolds. DNA substrates are shown in 
black ribbons. The NTSs are shown in cyan. The central repeat units are shown in yellow. The CTSs 
are shown in magenta. A hydrogen bond is shown in cyan.  
 
Using γ-H2AX as a marker of chromosomal DNA damage, we measured the 
nuclease-associated genotoxicities in human cells. Even though the increased genome 
editing efficacy of the SunnyTALEN scaffold is accompanied by increased DNA damage, 
γ-H2AX level can be reduced by lowering the TALEN dose or introducing obligate 
heterodimeric FokI nuclease domains (Figure 4.13). Because of the high efficiency of the 
SunnyTALEN scaffold, it can generate sufficient genetic modifications at dose-limiting 
conditions without causing detectable genotoxicities (Figure 4.7 and Figure 4.13). 
Because off-target cleavage is dependent on protein concentration as demonstrated for 
ZFNs (36), it is suggested to optimize the dose of SunnyTALENs for different human 
cell lines to achieve efficient genome editing with low toxicity. To avoid the off-target 
events generated by homodimeric ZFNs, obligate heterodimer mutations were introduced 
at the dimer interface of the FokI cleavage domain to prevent homodimerization based on 
128 
electrostatic and hydrophobic interactions (27,35,37). Similar principle was applied to 
TALENs and successfully reduced off-target cleavage and relieved toxicity (25). We 
show here that the incorporation of obligate heterodimeric FokI domains completely 
abolished the formation of cleavage-competent SunnyTALEN homodimers, resulting in 
reduced genotoxicity (Figure 4.12 and Figure 4.13).  
In conclusion, we isolated the high-efficiency SunnyTALEN scaffold using a directed 
evolution strategy. The SunnyTALEN scaffold is portable to many TALE DNA binding 
domains and compatible with heterodimer TALEN architectures. Although deployed here 
in yeast and human cells, the SunnyTALEN scaffold could be effective in various 
organisms and cell types. In addition to the GoldyTALEN scaffold that enables efficient 
genome modifications in zebrafish and livestock, the SunnyTALEN scaffold serves as a 
novel second-generation TALEN system and will aid in a variety of applications in 
medicine and biology. 
 
4.4. Materials and Methods 
4.4.1. Materials 
Q5 DNA polymerase, T4 DNA ligase, Antarctic phosphatase, and restriction 
endonucleases were purchased from New England Biolabs (Beverly, MA). QIAprep Spin 
Plasmid Miniprep Kit, QIAquick Gel Extraction Kit, and QIAquick PCR Purification Kit 
were obtained from Qiagen (Valencia, CA). Oligonucleotide primers were obtained from 
Integrated DNA Technologies (Coralville, IA). All the other reagents unless specified 
were obtained from Sigma-Aldrich (St. Louis, MO). 
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4.4.2. Yeast reporter strain 
To construct a single-strand annealing eGFP reporter, two separated eGFP fragments 
sharing a 100 bp homologous region were PCR amplified separately, digested with AvrII 
and XbaI, respectively, and ligated overnight at 16 °C. The ligation product was 
subsequently digested with a combination of AvrII and XbaI and the 870 bp non-cut 
fragment was gel-purified. The eGFP reporter gene was then cloned into the pRS414 
plasmid (New England Biolabs) between the ADH1 promoter and the ADH1 terminator. 
The centromere sequence of the plasmid was then removed by the PmlI digestion and 
blunt ligation. This plasmid was then digested with HindIII at the TRP1 gene. The 
linearized plasmid was transformed into S. cerevisiae HZ848 (MATα, ade2-1, ade3Δ22, 
Δura3, his3-11,15, trp1-1, leu2-3,112 and can1-100) using the LiAc/SS carrier 
DNA/PEG method (38) and stably integrated into the chromosome at the TRP1 site. The 
yeast reporter strain was obtained by selection of the transformed yeast cells on plates 
containing synthetic complete medium lacking tryptophan with 2% glucose at 30 °C. The 
integration was confirmed by PCR amplification and DNA sequencing of the targeted 
genomic region.  
 
4.4.3. Library creation 
The pRS415 yeast expression vector encoding the AvrXa10 TALEN that has been 
described previously (14) was used as the template for mutagenic PCR. The sequence 
encoding the CTS and FokI nuclease domain was mutagenized using the GeneMorph II 
Random Mutagenesis Kit (Stratagene, La Jolla, CA) according to the manufacturer's 
instruction. The following primers were used for the amplification: EP-FokI-Far-for 5’-
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ttg ttg ccc agt tat ctc gc-3’ and EP-FokI-Far-rev 5’-cgt gaa act tcg aac act gtc-3’. Two 
libraries with a low mutation rate (0-4.5 mutations/kbp) and a medium mutation rate (4.5-
9 mutations/kbp) were amplified and gel-purified, respectively. The TALEN expression 
plasmid was digested with AatII and SalI and gel-purified to remove the sequences 
encoding the wild-type CTS and FokI domain. The two gene libraries were mixed and 
co-transformed with the linearized TALEN expression plasmids at an approximately 13:1 
insert:vector molar ratio into the yeast reporter strain using the LiAc/SS carrier 
DNA/PEG method (38). Through yeast homologous recombination, the pRS415 plasmid 
library was created containing ~2×10
5
 transformants. 
 
4.4.4. High-throughput screening 
After transformation, the yeast reporter strain carrying the library of TALEN variants was 
recovered at 30 °C with shaking for 1 h in YPA medium (1% yeast extract, 2% peptone 
and 0.01% adenine hemisulphate) with 2% glucose. The cells were then centrifuged and 
resuspended in synthetic complete medium lacking leucine and tryptophan (SC-Leu-Trp) 
with 2% raffinose for growing at 30 °C with shaking overnight. TALEN expression was 
induced by culturing cells in YPA medium with 0.002-2% galactose at 30 °C for 1-6 h 
(the induction conditions for each cycle of screening are listed in Figure 4.5). The cells 
were then centrifuged and resuspended in SC-Leu-Trp liquid medium with 2% glucose at 
30 °C with shaking overnight. On the next day, cells were analyzed on a BD FACS Aria 
III cell sorting system (BD Biosciences, San Jose, CA) and 20,000-100,000 eGFP-
positive cells were collected. After 2 days’ growth at 30 °C in SC-Leu-Trp liquid medium 
with 2% glucose, plasmids from the sorted cells were extracted using Zymoprep Yeast 
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Plasmid Miniprep II Kit (Zymo Research, Orange, CA). Sequences encoding the CTS 
and FokI domain were PCR amplified from the plasmids by Q5 DNA polymerase and 
gel-purified for the next cycle of screening.  
 
4.4.5. A modified surrogate reporter system 
A TALEN target site within the HBB
S
 gene was inserted between the mRFP gene and the 
eGFP gene by overlap extension PCR. The fusion gene was cloned into the pLNCX2 
retroviral vector (BD Clontech, Palo Alto, CA) in the presence of the CMV promoter and 
stably integrated into the genome of Hela cells through retroviral transduction according 
to the manufacturer’s protocol. Transfected cells were selected in 500 μg/mL G418 for 
two weeks. The TALEN genes along with a FLAG tag sequence and a SV40 nucleus 
localization signal added to the N-terminus were cloned into the pCMV5 mammalian 
expression vector (39) through the KpnI and SalI sites.  
Reporter Hela cells were routinely maintained in the modified Eagle’s medium 
(MEM) supplemented with 10% Fetal Bovine Serum (FBS; Hyclone, Logan, UT). Cells 
were seeded in 24-well plates at a density of 5×10
4
 per well. After 24 h, reporter cells 
were transfected with certain amounts of TALEN expression plasmids using FuGene HD 
transfection reagent (Promega, Madison, WI) under conditions specified by the 
manufacturer. For each transfection, the overall plasmid amount was made to be 500 ng 
by adding the empty pCMV5 plasmid. Cells were trypsinized from their culturing plates 
48 h after transfection and resuspended in 300 μL phosphate buffered saline (PBS) for 
flow cytometry analysis. 20 000 cells were analyzed by a BD LSRII flow cytometer (BD 
Biosciences, San Jose, CA) to quantify the eGFP-positive cells.  
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4.4.6. Western blot analysis 
Hela cells in 12-well plates were harvested 24 h after transfection with pCMV5-TALEN-
HBB-R plasmid (14). Cells were collected by centrifugation, washed with PBS and 
resuspended in 40 μL whole cell lysis buffer (1 M Tris-HCl, pH 6.8, 20% sodium 
dodecyl sulfate, and 0.1 M dithiothreitol). Proteins were resolved by 4-20% Mini-Protean 
TGX Precast Gel (Bio-Rad Laboratories, Hercules, CA), transferred onto a nitrocellulose 
membrane, blocked for 1 h with Tris-buffered saline/0.05% Tween 20 containing 5% 
nonfat milk, followed by incubation with anti-FLAG tag (1: 500) and anti-α-tubulin (1: 
10 000) antibodies at 4 °C overnight. After incubation with anti-mouse horseradish 
peroxidase-conjugated secondary antibody (1: 25 000; GeneScript, Piscataway, NJ) for 1 
h, bands were visualized using SuperSignal West Pico Chemiluminescent Substrate 
(Pierce, Rockford, IL).  
 
4.4.7. TALEN construction 
The central repeat units of TALEs were assembled by the Golden Gate reactions as 
previously described (40). The receiver plasmids pCMV5-GG-WT for WT TALEN and 
pCMV5-GG-Sunny for the SunnyTALEN scaffold are available upon request. The NTS 
and CTS of the GoldyTALEN scaffold were PCR-amplified from pC-GoldyTALEN 
plasmid (Kindly provided by Dr. Daniel Carlson from University of Minnesota, 
Minneapolis, MN). 
 
4.4.8. SURVEYOR nuclease assay 
HEK293 cells in 6-well plates were harvested 48 h after transfection. Genomic DNA was 
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extracted using Wizard Genomic DNA Purification Kit (Promega, Madison, WI) 
according to the manufacturer’s instructions. DNA fragments containing TALEN target 
sites were PCR-amplified from the genomic DNA using the primers described previously 
(19). Gel-purified PCR products were re-annealed slowly and analyzed by SURVEYOR 
Mutation Detection Kits (Transgenomic, Omaha, NE) according to the manufacturer’s 
instructions. The product was resolved on a 2% agarose gel stained with GelStar (Lonza, 
Rockland, ME). The bands were quantified by G Box using Gene Tools software 
(Syngene, Frederick, MD). The apparent indel percentage of the original cell pool was 
calculated using the following equations as previously described (41):  
 
 Fraction cleaved = volume of cleaved bands/(volume of cleaved bands + volume 
of uncleaved bands) 
 % Indels = 100 × (1- (1- Fraction cleaved)
1/2
) 
 
4.4.9. H2AX phosphorylation assay 
HEK293 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% FBS. Cells were seeded in 12-well plates (2×10
5
 per well) and 
transfected after 24 h with 500 ng of each TALEN expression plasmid, 1 μg empty 
pCMV5 vector as a negative control or 1 μg reported toxic ZFN construct GZF3N 
(kindly provided by Dr. Toni Cathomen of Hannover Medical School, Hannover, 
Germany) as a positive control. After 48 h post transfection, cells were harvested, fixed, 
permeabilized, and stained using the H2AX phosphorylation assay kit (Millipore, 
Watford, UK) according to the manufacturer’s protocol. Cells were then scanned in a 
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flow cytometer to quantitate the number of cells staining positive for phosphorylated 
histone H2AX. 
 
4.4.10. Sequencing analysis of endogenous gene mutations 
HEK293 cells in 6-well plates were harvested 48 h after transfection with SunnyTALEN 
expression plasmids. Genomic DNA was extracted using Wizard Genomic DNA 
Purification Kit (Promega, Madison, WI) according to the manufacturer’s instructions. 
DNA fragments containing TALEN target sites within the BRCA2 gene were PCR-
amplified from the genomic DNA using the primers KpnI-BRCA2-for 5’-act gac ggt acc 
tga tct tta act gtt ctg ggt cac aaa-3’ (KpnI recognition site shown in italics) and SalI-
BRCA2-rev 5’-act gac gtc gac cgc cag gga aac tcc ttc ca-3’ (SalI recognition site shown 
in italics). DNA fragments containing TALEN target sites within the SS18 gene were 
PCR-amplified from the genomic DNA using the primers KpnI-SS18-for 5’-act gac ggt 
acc ggg atg cag gga cgg tca ag-3’ (KpnI recognition site shown in italics) and SalI-SS18-
rev 5’-act gac gtc gac gcc gcc cca tcc cta gag aaa-3’ (SalI recognition site shown in 
italics). PCR products corresponding to the two sites were cloned into pCMV5 plasmid 
between KpnI and SalI restriction sites. Plasmid DNA was isolated from 20 colonies for 
each transformation and then sent for Sanger sequencing using the primer pSeq-pCMV5-
for 5’-cgc aaa tgg gcg gta ggc gtg-3’. 
 
4.4.11. An eGFP gene conversion assay 
The eGFP gene was divided into two fragments by insertion of a preselected sequence 
from the HBB
S
 gene locus and an in-frame stop codon. The non-functional eGFP reporter 
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stably integrated into the genome of Hela cells as previously described (14). A donor 
plasmid was constructed by insertion of a promoter-less eGFP gene with the first 37 
nucleotides missing into the pNEB193 plasmid (New England Biolabs, Beverly, MA) as 
previously decribed (14). The donor plasmid provides a homologous DNA segment as a 
template for repairing the double-stranded break in the eGFP reporter. The reporter Hela 
cells were maintained in modified Eagle’s medium (MEM) supplemented with 10% Fetal 
Bovine Serum (FBS; Hyclone, Logan, UT). Cells were seeded in 12-well plates at a 
density of 1×10
5
 per well. After 24 hr, reporter cells were co-transfected with a certain 
amount of TALEN expression plasmids and 500 ng of donor plasmid using FuGene HD 
transfection reagent (Promega, Madison, WI) under conditions specified by the 
manufacturer. Cells were trypsinized from their culturing plates 48h after transfection and 
resuspended in 300 μL phosphate buffered saline (PBS) for flow cytometry analysis. 
20,000 cells were analyzed by BD LSRII flow cytometer (BD Biosciences, San Jose, CA) 
to determine the percentage of eGFP-positive cells.  
 
4.4.12. Computational modeling 
The homology models of TALEs with 63 aa CTSs were created by the I-TASSER online 
server (42) based on the crystal structure of dHax3 (PDB accession code: 3V6P) (43). 
The DNA-bound models were created based on the crystal structure of DNA-bound 
dHax3 (PDB accession code: 3V6T) (43) and energy minimized using the Molecular 
Operating Environment (MOE, The Chemical Computing Group, 2008) software 
package. The figures were generated using UCSF Chimera (44).  
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CHAPTER 5. DEVELOPMENT OF A SINGLE-CHAIN 
TALEN ARCHITECTURE 
 
5.1. Introduction 
Transcription-activator like effector (TALE) nucleases (TALENs) have been widely used 
for genome editing or engineering in various organisms during the last three years (as 
reviewed in (1,2)). The long DNA binding sequences of TALE DNA binding domains 
enable TALENs to target the custom-selected loci precisely with minimal off-target 
effects or cyto-tyxociteis. The simple one-repeat-one-nucleotide DNA recognition code 
of TALE DNA binding domains provides modular DNA reading, which enables 
researchers to target essentially any genomic region.  
The standard TALEN architecture is composed of TALE DNA binding domain, 
truncated N- and C-terminal extension and the non-specific DNA cleavage domain from 
a Type IIS restriction enzyme FokI (Figure 5.1A). Because the dimerization of the FokI 
cleavage domain is necessary for DNA cleavage activity (3), standard TALEN 
architecture requires two TALENs to bind to two DNA recognition regions flanking an 
unspecific central spacer. The optimal spacer length is dependent on the TALE scaffold 
construction (4-6). When the TALEN technology was initially developed, three 
limitations have been noticed to prevent its broader applications: a) the requirement of a 
5’-thymidine preceding the TALE binding sites can limit the targeting space; b) The 
highly repetitive nature of the TALE DNA binding domain makes it difficult to 
synthesize TALEN coding genes using traditional cloning strategy; c) The bulky size of  
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Figure 5.1. Schematic of standard and single-chain TALEN architectures. (A) Schematic of standard 
TALEN architecture. NTSs are represented by pink lines. CTSs are represented by magenta lines. 
TALEN binding sites are bold. (B) Schematic of scTALEN architecture. NTSs are represented by 
pink lines. CTSs are represented by magenta lines. TALEN binding sites are bold. A polypeptide 
linker that connects two FokI domains is represented by a red line.  
 
TALENs possess the challenge of efficiently delivering corresponding DNA, RNA or 
proteins into certain cell types. In Chapter 2, we demonstrated that the requirement of 
the 5’-T can be mitigated by using a specific TALEN architecture with 63 amino acid C-
terminal extension (6). Other studies also provided evidence that a thymine at position 0 
is not strictly required for TALEN activity (4,7,8), indicating that the first limitation has 
been successfully addressed. The problem of synthesizing highly repetitive TALE genes 
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has also been solved by multiple groups by the introduction of Golden Gate cloning, 
solid-phase ligation and ligation-independent cloning techniques (7,9-14).  
In order to address the third limitation, i.e. reduce the TALEN size, Beurdeley and 
coworkers have developed a compact TALEN (cTALEN) architecture by replacing the 
requisite dimeric FokI cleavage domain with the DNA cleavage domain from the I-TevI 
homing endonuclease (15). In this design, cTALENs can cleave the targeted DNA 
sequence as a monomer and thus reduce the TALEN payload to half as compared with 
the conventional TALEN architecture. However, unlike the non-specific FokI DNA 
cleavage domain, the I-TevI DNA cleavage domain has its own DNA recognition 
sequence. They discovered that the efficient DNA cleavage of cTALEN is dependent on 
the consensus sequence CDDHGS (D= A, G or T; H= A, C or T; S= C or G), which is 
outside the TALE binding site. Therefore, the native DNA recognition specificity of I-
TevI DNA cleavage domain severely decreases the targeting space of cTALENs. In this 
chapter, I describe the development of a single-chain TALEN (scTALEN) architecture, in 
which two FokI DNA cleavage domains are linked by a polypeptide linker (Figure 5.1B). 
The appropriate linker is isolated from the high-throughput screening of a polypeptide 
linker library. In this design, the two FokI domains on the same polypeptide can form a 
catalytic active self-dimer and thus make scTALENs to function as monomers. The 
scTALEN architecture I have developed reduced the TALEN payload to half as 
compared to standard TALEN architecture. Moreover, because the FokI DNA cleavage 
domains have no DNA recognition specificity, the DNA target sequence is solely 
determined by the TALE DNA binding sites. Therefore, scTALENs can be used to target 
essentially any DNA sequence.  
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5.2. Results 
5.2.1. Construction of a scTALEN library 
Since FokI dimerization is required for DNA cleavage activity (3), we set out to construct 
a scTALEN by linking two FokI DNA cleavage domains with a polypeptide linker. 
Presumably the length and amino acid composition is critical to the formation of the 
intra-molecular FokI dimer. Because our knowledge is still limited for designing a 
functional linker de novo, we decided to apply the principle of directed evolution and 
screen one functional linker from a polypeptide linker library. The linker library is 
composed of various polypeptide linkers ranging from 30 to 120 amino acids with 
different sequences as previously described (16). At the beginning we generated a linker 
recipient expression vector with two FokI coding sequences separated by BamHI and 
XhoI restriction sites (Figure 5.2A). The library of polypeptide linkers were then inserted 
into the linker recipient expression vector to generate the library of scTALENs, in which 
the two FokI cleavage domains were joined by polypeptide linkers of varying length and 
amino acid composition. The complexity of the corresponding library is approximately 
2×10
5
. Each linker shared two common flanking polypeptides (GSGSGS) at both N- and 
C- termini. Theses Gly-Ser repeats were incorporated during construction of the linker 
library to provide flexible regions flanking linkers in order to minimize disruption of 
well-ordered domains or folds. The N-terminal Gly-Ser (BamHI site) and C-terminal Gly-
Ser-Ser (including XhoI site) provided additional flexibility for further manipulation or 
linker transfer (Figure 5.2A & C).  
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Figure 5.2. High-throughput screening of active scTALENs. (A) Schematic of a recipient expression 
vector. The peptide linkers with various lengths and sequences were cloned using the BamHI and XhoI 
sites. GAL10p, promoter of GAL10 gene; CEN6, a centromere of yeast chromosome. LEU2 
auxotrophic marker is used for selection of transformants in yeast. (B) Schematic representation of the 
high-throughput screening in yeast for isolating active scTALENs. (C) Sequence information of the 
peptide linker from the isolated scTALEN. Common flanking polypeptides are shown in red. The N-
terminal Gly-Ser (BamHI site) and C-terminal Gly-Ser-Ser (including XhoI site) are underlined.  
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5.2.2. High-throughput screening of active scTALENs 
To identify catalytically active scTALENs in the library, we applied a high-throughput 
screening system in yeast as described in Chapter 4. This system couples the catalytic 
activity of a scTALEN with the enhanced green fluorescence protein (eGFP) signal 
(Figure 4.1). The expression of scTALEN was induced by galactose and the GFP-
positive cells were collected by fluorescence-activated cell sorting (FACS). The sorted 
cells were pooled together and plasmids from the pool were isolated. The plasmids 
obtained from yeast cell miniprep were retransformed to E. coli and extracted again to 
increase plasmid quantity and quality. This process was continued in an iterative fashion 
until the scTALENs with catalytic activity were enriched and identified (Figure 5.2B). 
After three rounds of enrichments, we were able to identify one scTALEN architecture 
with two FokI domains linked by a polypeptide with 95 residues (Figure 5.2C). To 
characterize the isolated scTALEN architecture, we compared its activity with the 
standard TALEN architecture and a homing endonuclease I-CreI in the LacZ-based yeast 
reporter system as described in Chapter 2. The cleavage activities of these DNA 
endonucleases were indicated by the corresponding β-galactosidase activities (Figure 
2.2). Whereas the conventional TALEN has no activity as a monomer, the scTALEN we 
isolated exhibited 13% activity as compared with I-CreI (Figure 5.3). To rule out the 
possibility that the obtained activity is from the evolution of the vector during high-
throughput screening, we sub-cloned the scTALEN gene into a new expression vector. 
The recloned scTALEN expression plasmid showed similar activity as compared with the 
original scTALEN expression plasmid, confirming that the DNA cleavage activity is 
from the scTALEN open reading frame (Figure 5.3).  
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Figure 5.3. Activity of scTALEN in yeast cells as measured by the β-galactosidase assay (schematic 
of the assay is shown in Figure 2.2). Error bars indicate standard deviation of at least three 
independent experiments. 
 
5.2.3. In vivo activity in human cells 
To test the in vivo activity of the isolated scTALEN in human cells, we measured the 
genome editing efficiency in the modified surrogate reporter system as described in 
Chapter 4. The reporter construct encoding a monomeric red fluorescent protein 
(mRFP)-eGFP fusion protein was stably integrated into the genome of Hela cells. A 
TALEN target site within sickle human β-globin (HBBS) gene locus (Table 4.1 and 
Figure 5.1) (6) was inserted between the mRFP and eGFP genes, making the eGFP gene 
out of frame. In response to the TALEN-induced DNA cleavage, certain insertions and 
deletions caused by non-homologous end joining will make the eGFP gene in frame and 
restore eGFP function. Pairwise comparison was performed between conventional 
TALEN monomers and scTALEN architectures bearing the HBB-F and HBB-R DNA  
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Figure 5.4. Activity of scTALENs in human cells as tested in the modified surrogate reporter system 
(schematic of the assay is shown in Figure. 4.6).  
 
binding domains (Figure 5.1). The cells transfected with conventional TALEN 
monomers exhibited minimal GFP signals which were almost identical to background 
noise (Figure 5.4). However, the scTALEN monomers increased the GFP signal by over 
twofold. Although the scTALENs showed only 1-2% activities as compared to standard 
TALEN heterodimers, the scTALEN architecture we identified demonstrates an 
important proof-of-concept that FokI-based single-chain TALEN can be active in human 
cells. The scTALEN were then applied to target three endogenous sites of human genome 
with modest but significant activities (Figure 5.5). Western blot analysis indicates that 
the polypeptide linker and another FokI DNA cleavage domain in the scTALEN 
architecture do not change protein expression levels in human cells (Figure 5.6).  
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Figure 5.5. Application of the scTALEN architecture for human genome editing. SURVEYOR 
nuclease assay (procedure is described in 4.4.8) was performed to determine the frequencies of  
scTALEN-induced gene modifications. 
 
 
Figure 5.6. Western blot analysis for the expression of TALEN variants. All the TALEN variants 
contained a FLAG tag at the N-terminus. α-tubulin was used as an internal control.  
 
5.3. Discussion 
In this study, I developed a scTALEN architecture by fusing two FokI DNA cleavage 
domains at the C-terminus of the TALE DNA binding domain. A similar strategy has 
been applied for the construction of single-chain zinc finger nucleases (17,18). However, 
151 
the flexible (GGGGS)n linkers used in the two studies were not functional for the 
construction of scTALEN architecture (data not shown). To facilitate the dimerization of 
the two FokI domains on the same polypeptide chain, an appropriate linker with certain 
length and secondary structure is critical. Because the tools are still lacking for the design 
of a functional linker de novo, a directed evolution strategy was harnessed to isolate a 
functional peptide linker from a library of linkers with various lengths and sequences.  
The scTALEN architecture I have developed showed only moderate in vivo activity in 
both yeast and human cells. Therefore, further studies are needed to improve its genome 
editing efficacy. Using this scTALEN as a template, I created another scTALEN library 
by the introduction of random mutations on the FokI-linker-FokI region. Three rounds of 
directed evolution were carried out using the same high-throughput screening system. 
However, no mutant with increased activity can be isolated, indicating the limitation of 
the screening system. A detailed structural analysis of the 95 amino acid polypeptide 
linker can provide a detailed mechanism of the formation of an intra-molecular FokI 
dimer. This structural information can also be helpful in the design of more active linkers 
using rational protein design. Despite the low in vivo activity, the scTALEN architecture 
I have developed represents the first example of single-chain FokI-based TALEN, which 
represents a very important proof-of-concept that a FokI dimer can be formed in a single 
polypeptide chain and paves the road for future protein engineering endeavors.  
 
5.4. Materials and Methods 
5.4.1. Materials 
Q5 DNA polymerase, T4 DNA ligase, Antarctic phosphatase, and restriction 
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endonucleases were purchased from New England Biolabs (Beverly, MA). QIAprep Spin 
Plasmid Miniprep Kit, QIAquick Gel Extraction Kit, and QIAquick PCR Purification Kit 
were obtained from Qiagen (Valencia, CA). Oligonucleotide primers were obtained from 
Integrated DNA Technologies (Coralville, IA). All the other reagents unless specified 
were obtained from Sigma-Aldrich (St. Louis, MO). 
 
5.4.2. Yeast eGFP reporter strain 
The single-strand annealing eGFP reporter on pRS414 vector with two separated eGFP 
fragments sharing a 100 bp homologous region was described in Chapter 4. The 
centromere sequence of the plasmid was then removed by the PmlI digestion and blunt 
ligation. This plasmid was then digested with HindIII within the TRP1 gene. The 
linearized plasmid was transformed into S. cerevisiae HZ848 (MATα, ade2-1, ade3Δ22, 
Δura3, his3-11,15, trp1-1, leu2-3,112 and can1-100) using the LiAc/SS carrier 
DNA/PEG method (19) and stably integrated into the chromosome at the TRP1 site. The 
yeast reporter strain was obtained by selection of the transformed yeast cells on plates 
containing synthetic complete medium lacking tryptophan with 2% glucose at 30 °C. The 
integration was confirmed by PCR amplification and DNA sequencing of the targeted 
genomic region.  
 
5.4.3. Creation of a scTALEN library 
The yeast TALEN expression vector with pRS415 backbone was described in Chapter 2. 
This vector was digested with HindIII and SalI to remove the latter part of the FokI 
coding sequence. Ligation of this digested vector and a PCR product amplified by the 
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primers FokI-middle(HindIII)-for 5’-gga tac taa agc tta tag cgg agg-3’ (HindIII site 
shown in italic) and SalI-XhoI-BamHI-FokI-rev 5’-atc cgc gtc gac act gac tga ctg act cga 
gcc tac tga ctg tta gga tcc aaa gtt tat ctc gcc gtt’3’ (XhoI site underlined and BamHI site 
shown in italic) digested with HindIII and SalI makes plasmid pRS415-GAL10P-N3-C1-
Xa10-BamHI-XhoI. An additional copy of FokI coding region was inserted into this 
vector between the XhoI and SalI sites to generate the recipient expression vector (Figure 
5.2A).  
The polypeptide linker library was kindly provided by Dr. David Baker from the 
University of Washington (Seattle, WA). The sequences encoding the linker library was 
PCR amplified by primers: BamHI-linkerlib-forN 5’-act gac gga tcc ggt agc ggc tca gga-
3’ (BamHI site shown in italics) and XhoI-linkerlib-revN 5’-act gac ctc gag cc g ctt ccc 
gac cca ga-3’ (XhoI site shown in italics). The PCR product has various lengths and 
showed a smeared wide band on 2% agarose gel. All of the PCR products were gel-
extracted, digested with XhoI and BamHI, purified, and inserted into the recipient 
expression vector that was digested with the same restriction enzymes. The ligation 
products were precipitated by 1-butanol and electroporated into DH5α competent cells to 
create the library of scTALENs. The library contains approximately 2×10
5
 transformants 
(data not shown).  
 
5.4.4. High-throughput screening 
The plasmids were minipreped from the scTALEN library and transformed into the 
reporter yeast strain as described above using the LiAc/SS carrier DNA/PEG method (19). 
After transformation, the yeast cells were recovered at 30 °C with shaking for 1 h in YPA 
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medium (1% yeast extract, 2% peptone and 0.01% adenine hemisulphate) with 2% 
glucose. The cells were then centrifuged and resuspended in synthetic complete medium 
lacking leucine and tryptophan (SC-Leu-Trp) with 2% raffinose for growing at 30 °C 
with shaking overnight. TALEN expression was induced by culturing cells in YPA 
medium with 2% galactose at 30 °C for 5 h. The cells were then centrifuged and 
resuspended in SC-Leu-Trp liquid medium with 2% glucose at 30 °C with shaking 
overnight. On the next day, cells were analyzed on a BD FACS Aria III cell sorting 
system (BD Biosciences, San Jose, CA) and 20,000-100,000 eGFP-positive cells were 
collected. After 2 days’ growth at 30 °C in SC-Leu-Trp liquid medium with 2% glucose, 
plasmids from the sorted cells were extracted using Zymoprep Yeast Plasmid Miniprep II 
Kit (Zymo Research, Orange, CA). The plasmids were then electroporated into DH5α 
competent cells for amplification. The minipreped plasmids were subjected to the next 
round of screening.  
 
5.4.5. LacZ reporter assay in yeast 
The yeast reporter system based on lacZ gene was described in Chapter 2. To test the in 
vivo cleavage activity of scTALENs in the yeast reporter system, both the pRS414 
reporter plasmid and pRS415 expression plasmid were transformed into Saccharomyces 
cerevisiae HZ848 (MATα, ade2-1, ade3Δ22, Δura3, his3-11,15, trp1-1, leu2-3,112 and 
can1-100). After 3-4 days growth at 30 °C on SC-Leu-Trp plates with 2% glucose, three 
transformants were picked to grow in SC-Leu-Trp liquid medium with 2% galactose. 
After cultivation for 2 days at 30 °C, yeast cells were harvested by centrifugation and 
lysed by Y-PER yeast protein extraction reagent (Pierce, Rockford, IL). The β-
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galactosidase (β-GAL) enzyme activity was determined by the β-galactosidase enzyme 
system from Promega (Madison, WI) according to the manufacturer's instruction. For 
each sample, the β-GAL activity was measured as a function of time and normalized by 
total protein concentration determined using the BCA protein assay (Pierce, Rockford, 
IL). Homing endonuclease I-CreI (20) and conventional dimeric TALENs served as 
positive controls.  
 
5.4.6. In vivo activity in human cells 
The pCMV5 TALEN expression plasmids were reported in Chapter 2. To construct 
scTALEN expression vectors for human cells, the FokI-linker-FokI coding sequence of 
scTALEN was PCR amplified from the pRS415 plasmids. The PCR products were then 
digested with AflII and SalI and inserted into the AflII/SalI digested pCMV5 TALEN 
expression plasmids to make pCMV5 scTALEN expression plasmids by replacing the 
FokI genes with the FokI-linker-FokI coding sequences.  
A modified surrogate reporter system in human cells was described in Chapter 4. 
Reporter Hela cells were routinely maintained in the modified Eagle’s medium (MEM) 
supplemented with 10% Fetal Bovine Serum (FBS; Hyclone, Logan, UT). Cells were 
seeded in 24-well plates at a density of 5×10
4
 per well. After 24 h, reporter cells were 
transfected with 1 μg of pCMV5 scTALEN expression plasmids using FuGene HD 
transfection reagent (Promega, Madison, WI) under conditions specified by the 
manufacturer. Cells were trypsinized from their culturing plates 48 h after transfection 
and resuspended in 300 μL phosphate buffered saline (PBS) for flow cytometry analysis. 
20 000 cells were analyzed by a BD LSRII flow cytometer (BD Biosciences, San Jose, 
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CA) to quantify the eGFP-positive cells.  
 
5.4.7. Western blot analysis 
Hela cells in 12-well plates were harvested 24 h after transfection with TALEN 
expression plasmids. Cells were collected by centrifugation, washed with PBS and 
resuspended in 40 μL whole cell lysis buffer (1 M Tris-HCl, pH 6.8, 20% sodium 
dodecyl sulfate, and 0.1 M dithiothreitol). Proteins were resolved by 4-20% Mini-Protean 
TGX Precast Gel (Bio-Rad Laboratories, Hercules, CA), transferred onto a nitrocellulose 
membrane, blocked for 1 h with Tris-buffered saline/0.05% Tween 20 containing 5% 
nonfat milk, followed by incubation with anti-FLAG tag (1: 500) and anti-α-tubulin (1: 
15 000) antibodies at 4 °C overnight. After incubation with anti-mouse horseradish 
peroxidase-conjugated secondary antibody (1: 15 000; GeneScript, Piscataway, NJ) for 1 
h, bands were visualized using SuperSignal West Pico Chemiluminescent Substrate 
(Pierce, Rockford, IL).  
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